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1. INTRODUCTION 
1.1. BACKGROUND 
 
Parkinson’s Disease (PD) is a neurodegenerative disease related to the 
dopaminergic neuron loss of the Substantia Nigra pars compacta (SNpc) 
(Scalzo et al., 2010), which is clinically characterized by bradykinesia, 
hypokinesia, resting tremor, rigidity and postural instability (Hausdorff, 2009). 
The annual incidence rate of disease has been estimated to range from 16 to 
19 per 100,000 persons affected, mainly over 50 years, with prevalence and 
incidence rates increasing with age (Pahwa and Lyons, 2010). 
Clinically, the disease is heterogeneous and it develops in different ways 
for each patient. Subtypes may be recognized on the basis of age of onset, 
predominant clinical features and progression rate. There are two principal 
clinical subtypes: a tremor predominant form that is often found in younger 
people, and a type characterized by a postural imbalance and a gait disorder 
that is often observed in older people (>70 years old) distinguished by akinesia, 
rigidity, and gait and balance impairment. The first subtype leads to a slow 
decline of motor function, whereas the second subtype worsens more rapidly 
(Obeso et al., 2010). The clinical diagnosis of PD is typically based on the 
presence of cardinal motor features, absence of atypical findings suggestive of 
an alternative diagnosis, and response to levo-3, 4-dihydroxyphenylalanine (L-
DOPA) (Perfeito et al., 2013). 
In addition to the loss of dopaminergic neurons in the SNpc, PD is 
neuropathologically characterized by the presence of Lewy bodies, 
intracytoplasmic eosinophilic inclusions found in injured or fragmented neurons, 
(Burch, Sheerin, 2005) with -synuclein as the major fibrillar component 
(Spillantini et al., 1997; Baba et al., 1998). However, the exact mechanism 
underlying selective dopaminergic neurodegeneration is still not understood. It 
is believed that many cellular mechanisms may be involved, including oxidative 
stress, intracellular Ca2+ homeostasis impairment, and mitochondrial 
dysfunctions (Cali et al., 2011).  
Although most cases of PD occur sporadically, mutations in several genes 
have been linked to genetic forms of PD, including at least 13 gene loci and 
nine genes that are related to both autosomal dominant and recessive forms of 
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PD. Mutations in three proteins encoded by these genes, namely parkin 
(PARK2), DJ-1 (PARK7), and PINK1 (PARK6), are associated with recessive 
early-onset forms of PD, whereas mutations in -synuclein (PARK1-4) and 
LRRK2 (PARK8) are responsible for dominant forms of familial PD. The activity 
and cellular distribution of the proteins encoded by these genes are different 
and still not completely elucidated. PINK1 and LRRK2 are kinases, DJ-1 is a 
multifunctional protein that acts as peptidase, chaperone redox/oxidative 
sensor, transcriptional modulator, and oncogene, parkin is a E3-ubiquitin ligase 
and -synuclein, in addition to be the principal component of Lewy bodies, plays 
important role in the regulation of vesicles trafficking (Cali et al., 2011). Among 
these proteins, PINK1 and Parkin play crucial roles in the regulation of 
mitochondrial dynamics and function (Gandhi et al., 2009). Mutations in DJ-1 
and Parkin render animals more susceptible to oxidative stress (Gandhi et al., 
2009). Moreover, mitochondrial association of -synuclein in cells was also 
linked to impairment of respiratory complex I activity, oxidative modification of 
mitochondrial proteins, and increased levels of Ca2+ (Cannon et al., 2013; Liu et 
al., 2009; Li et al., 2013). Alterations in the mitochondrial complex I are also 
found in autoptic samples of substantia nigra from patients affected with the 
disease in which the activity of complex I was shown to be reduced (Parker et 
al., 2008). 
As mentioned above, many evidences described in the literature seem to 
converge on mitochondria as a primary target in the process of dopaminergic 
neuronal loss observed in PD. Any alteration in the mitochondrial functionality 
seems to deeply affect the ability to support cellular stresses, thus making the 
cells more susceptible to additional insults. Therefore, dysfunction in 
mitochondria results in a deficit supply of cellular energy and in a failure in 
maintaining cellular homeostasis with particular regards to calcium 
homeostasis. These events play a central role in apoptotic and necrotic cell 
death pathway leading to neurodegeneration  (Ghosh et al., 1999; Banerjee et 
al., 2009). Indeed, perturbations of calcium homeostasis are common 
denominator in several neurodegenerative disorders including PD. In fact, SNpc 
dopaminergic neurons have a singular characteristic in respect to the other 
groups of neurons. Dopaminergic neurons are autonomously active, being 
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characterized by a pace making activity responsible to generate action 
potentials also in the absence of synaptic input. This activity exposes 
dopaminergic neurons to large Ca2+ influx (Surmeier et al., 2009). Furthermore, 
it has been reported that an increased activity of several classes of Ca2+ 
channels including L-type voltage-dependent-and cyclic nucleotide-sensitive 
channels seem to play a key role in the pathogenesis of Parkinson's disease, 
leading to an alteration of intracellular Ca2+ homeostasis. Moreover, the recent 
observation that cells deficient in complex-I showed an alteration in the cytosolic 
calcium handling, reduced mitochondrial calcium accumulation and consequent 
ATP synthesis (Visch et al., 2004), suggested a possible relationship between 
mitochondrial dysfunction and perturbation of intracellular calcium homeostasis 
in the pathogenesis of PD. 
 
1.2 Pathogenesis of Parkinson’s Disease 
1.2.1 Mitochondrial dysfunction during Parkinson’s Disease 
 
Mitochondrion is intracellular membrane enclosed organelle found in most 
eukaryotic cells, which plays several important cellular functions, such as the 
production of energy by oxidative phosphorylation, the regulation of calcium 
homeostasis, and the control of programmed cell death. Furthermore, 
mitochondria are dynamic organelles that actively divide, fuse with one another, 
and undergo regulated turnover, all of which is important for the maintenance of 
mitochondrial function and quality control (Perier and Vila, 2011). 
According to a widespread concept, neurons are critically dependent on 
mitochondrial integrity based on their specific morphological, biochemical, and 
physiological features. Indeed, neurons are characterized by high rates of 
metabolic activity and need to respond promptly to activity-dependent 
fluctuations in bioenergetic demand. The dimensions and polarity of neurons 
require efficient transport of mitochondria to hot spots of energy consumption, 
such as presynaptic and postsynaptic sites. Consequently, alterations in any of 
these mitochondrial features can potentially cause disease and have been 
linked to the pathogenesis of neurodegenerative diseases including Parkinson’s 
disease (Exner et al., 2012). In particular, defective mitochondrial respiration, at 
the level of complex I, has long been associated with the pathogenesis of PD. 
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Evidence of this involvement first emerged after the observation that accidental 
exposure of drug abusers to 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine 
(MPTP), an inhibitor of mitochondrial complex I, resulted in an acute and 
irreversible parkinsonian syndrome almost indistinguishable from PD (Langston 
et al., 1983). It was subsequently shown that MPTP, when injected into non 
human primates and mice, selectively kills dopaminergic neurons of the 
substantia nigra pars compacta (SNpc), the type of cells that preferentially 
degenerate in PD (Dauer and Przedborski 2003). Similarly, chronic infusion of 
the potent complex I inhibitor rotenone to rats has been reported to produce 
nigrostriatal dopaminergic neurodegeneration (Betarbet et al., 2000). A link 
between complex I dysfunction and PD was further established when several 
groups reported that a reduction in complex I activity occurs in the brain, 
platelets, and skeletal muscle of patients with sporadic PD (Parker et al., 1989; 
Schapira et al., 1990). 
As a consequence of complex I dysfunction, it was found a reduction in 
ATP production and subsequent bioenergetic failure. Supporting this view, 
MPP+ (MPTP’s active metabolite) causes a rapid and profound depletion of 
cellular ATP levels in hepatocytes (Di Monte et al., 1986), in brain synaptosomal 
preparations (Scotcher et al., 1990) and in whole mouse brain tissues (Chan et 
al., 1991). Another consequence of complex I inhibition is the formation of 
reactive oxygen species (ROS), which damage mitochondria DNA (mtDNA), 
components of the respiratory chain and other mitochondrial factors, thereby 
triggering a vicious circle between mitochondrial impairment and oxidative 
stress (Exner et al., 2012). 
The subsequent discovery of hereditary forms of PD caused by dominant 
and recessive mutations in nuclear genes encoded proteins functionally related 
to mitochondria has added additional importance to the study of mitochondrial 
dysfunction in PD. The products of two dominantly inherited genes, α-synuclein 
and LRRK2, and of several autosomal recessive inherited genes, DJ-1, parkin, 
PINK1 and Omi/HTRA2, have been found to be localized in, and/or to interfere 
with mitochondria (Liu et al., 2009; Cali et al., 2012). In addition, PD-like protein 
DJ-1 has been identified as a mitochondrial peroxi-redoxin-like peroxidase, able 
to scavenge mitochondrial ROS; its deficiency in mutant mice results in 
increased mitochondrial ROS production (Perier and Vila, 2012). Indeed, PINK1 
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has been linked to a number of a physiological role such as, the 
phosphorylation of mitochondrial proteins in response to cellular stress and the 
protection against mitochondrial dysfunction (Gandhi et al., 2009; Ziviani et al., 
2010; Akundi et al., 2011). There is evidence that wild type PINK1, in contrast to 
mutant PINK1, may protect neurons from stress-induced mitochondrial 
dysfunction and apoptosis (Perfeito et al., 2013). Furthermore, loss of PINK1 
function in human cell lines produced morphological changes in mitochondria 
impaired energy metabolism, and decreased mitochondrial membrane potential 
(Exner et al., 2007). Recently, few studies considered the possibility that these 
mutations may be also involved in mitochondrial Ca2+ signaling. There is 
evidence that α-synuclein modulates Ca2+ influx (Buttner et al., 2013), 
suggesting that its oligomers promote alterations in calcium dynamics via 
interference with intracellular buffering mechanisms. In another study it was 
found that overexpression of Parkin increased mitochondrial Ca2+ transients by 
enhancing endoplasmic reticulum-mitochondria interactions (Cali et al., 2013).  
Furthermore, Ca2+ accumulation in the mitochondrial matrix results at an 
energetic cost, as it dissipates the electrochemical gradient created by 
respiratory metabolism along the electron transport chain (ETC) (Chan et al., 
2010) and also leads to a disruption of mitochondrial membrane integrity, 
permeability transition, irreversible oxidative damage and consequently cell 
death (Cali et al., 2012). 
 
1.2.2 Dysregulation of calcium concentration and neurodegeneration 
 
Ca2+ is the main second messenger that helps to transmit depolarization 
status and synaptic activity to the biochemical machinery of a neuron. In 
neurons, Ca2+ have multiple complex and integrated functions, including the 
control of dendritic responses to neurotransmitters, signalling to the nucleus to 
regulate gene expression, and initiation of neurotransmitter release from 
presynaptic axon terminals (Gleichmann and Mattson, 2011). In these ways 
Ca2+ plays pivotal roles in controlling neuronal excitability. Thus, Ca2+ functions 
as a key regulator of electrochemical signalling, not only within individual 
neurons, but also among large populations of neurons that comprise neuronal 
networks (Gleichmann and Mattson, 2011).  
 9 
The influx of Ca2+ through voltage-dependent and ligand-gated channels in 
the plasma membrane is a critical signal for the release of the neurotransmitters 
from presynaptic terminals and for responses of the postsynaptic neuron 
(Mattson 2007). Glutamate, an excitatory neurotransmitter in the central 
nervous system, induces local and general increases of cytoplasmic Ca2+ 
through the activation of AMPA and NMDA receptors in the plasmamembrane, 
with consequent activation of voltage-dependent Ca2+ channels (VDCC) (Cali et 
al., 2011). In addition, the activation of metabotropic glutamate receptors 
coupled to the GTP-binding protein Gq11 stimulates the release of inositol 
triphosphate (IP3), which activates Ca
2+ channels in the endoplasmic reticulum 
(Mattson, 2007). 
The cost for extensive neuronal Ca2+ signalling is an increased energy 
demand because all the Ca2+ that enters in neurons must be removed from the 
cytoplasm by ATP-dependent membrane calcium pumps in order to maintain 
Ca2+ homeostasis (Gleichmann and Mattson, 2011). Moreover, Ca2+ is removed 
from the cytoplasm thank to the activity of the plasma membrane Na2+/Ca2+ 
Exchanger (NCX), the plasma membrane and endoplasmatic reticulum (ER) 
Ca2+-ATPases, and the Ca2+-bindings proteins such as calbidin and 
parvalbulmin. Finally, Ca2+ can also be transported into and released from 
mitochondria (Mattson, 2007). 
In the dopaminergic neurons of the SNpc, that have most of Ca2+channels 
open much of the time due to their pace making activity, the magnitude of the 
Ca2+ influx appears to be much larger and the charge to the cell much greater 
compared to neurons in other different brain regions (Chan et al., 2010). 
Because of the slow kinetics of the plasma membrane transporters and their 
restriction to the cellular surface, Ca2+ entering neurons must be rapidly 
sequestered either in organelles lying below the plasma membrane or through 
ionic interactions with mobile buffering proteins before being escorted out of the 
cell. Mitochondria and the endoplasmic reticulum (ER) are the principal 
organelles involved in sequestering Ca2+ in neurons (Rizzuto and Pozzan, 2006; 
Verkhratsky, 2005). The ER uses high-affinity ATP-dependent transporters to 
take Ca2+ from the cytoplasm into the ER lumen. As this store fills up, Ca2+ 
triggers the opening of ER Ca2+ channels that let the Ca2+ flow back into the 
cytoplasm. These channels are often found in close apposition to mitochondria 
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and their opening creates a region of high-local Ca2+ concentration that drives 
influx of Ca2+ into the matrix of mitochondria through Ca2+ uniporters (Rizzuto 
and Pozzan, 2006). Ca2+ accumulation in the mitochondrial matrix again comes 
at an energetic cost, as it dissipates the electrochemical gradient created by 
respiratory metabolism along the electron transport chain (ETC). In fact, an 
important feature of the mitochondrial Ca2+ transport pathway is that this 
organelle contains low calcium in resting cells, but is able to accumulate large 
amounts of calcium in condition stimulating Ca2+ entry, and to release this 
calcium loaded during the recovery phase (Nicholls, 2005). This is due to the 
ability of specific transporters localized on the inner mitochondrial membrane 
that allow calcium to cycle from mitochondrial matrix to the cytosol and from the 
cytosol to the mitochondrial matrix. Ca2+ is removed from the matrix through the 
mitochondrial NCX (Kim and Matsuoka, 2008; Rizzuto and Pozzan, 2000), the 
Ca2+ proton exchanger (Williams and Fry, 1979), and the transient opening of 
the mitochondrial permeability transition pore (mPTP) (Hüser and Blatter, 1999). 
These events allow the maintenance of mitochondrial calcium concentrations 
within physiological range that are necessary for the neurons to adjust aerobic 
ATP production, to regulate synaptic transmission and excitability, to promote 
organelle dynamics and trafficking, to mediate signalling to nucleus, to control 
the generation of ROS, and to preserve neuronal survival (Nicholls, 2005; 
Starkov, 2002; Chinopoulos and Adam-Vizi, 2010; Duchen, 2004; Mattson et 
al., 2008). 
ER is another important organelle responsible to maintain Ca2+ 
homeostasis into neurons. The ER is able to store Ca2+ within the cell thanks to 
its intralumial Ca2+ capacity of about 0.5 mM. Ca2+ is pumped into the ER by 
sarcoplasmic endoplasmic reticulum Ca2+ ATPase (SERCA) and is extruded by 
IP3-RS and RyRs channels (Gleichmann and Mattson, 2011). The regulation of 
Ca2+ release from this organelle is responsible for many neuronal functions, 
from plasmalemmal excitability to synaptic plasticity. Together with 
mitochondria, ER forms junctions that support signal transduction and 
biosynthetic pathways and affect distribution of the organelles. These junctions 
have a pivotal role in mediating Ca2+ signal propagation to the mitochondria 
(Zundorf and Reiser, 2011). 
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During normal physiological activity, the intracellular Ca2+ concentration 
increases only transiently and has no adverse effects on the neurons. However, 
in pathological conditions, and in normal aging, the ability of neurons to control 
Ca2+ effluxes and recover from a Ca2+ load is compromised (Mattson, 2007). 
Perturbations in calcium homeostasis are common denominator in several 
neurodegenerative disorders including PD (Surmeier, 2007). However, the 
molecular mechanisms responsible for the selective loss of neuronal population 
in the different neurodegenerative disorders are less clear. Several hypothesis 
have been made, originally based on dopamine implication and proposing that 
dopamine cytosolic oxidation (and its metabolites) may cause toxic effects 
through the generation of free radicals (Greenamyre and Hastings, 2004). 
However, this pathway cannot be the only responsible for the selective neuronal 
loss as, not all dopaminergic neurons in the brain die in PD. Recently, an 
interesting hypothesis has been provided to explain the reason why SNpc 
dopaminergic neurons are particularly vulnerable and it takes into account their 
peculiar physiology. In fact, SNpc dopaminergic neurons, with difference to the 
large majority of other neurons, are autonomously active, being characterized 
by a pace making activity responsible to generate action potential also in the 
absence of synaptic input (Grace and Bunney, 1983). This characteristic 
depends on the structural properties of L-Type Ca2+ channels, characterized by 
the presence of Cav1.3 pore forming subunit, that confers to this type of 
Ca2+channels the property to be open at relatively hyperpolarized potentials and 
thus exposing SNpc dopaminergic neurons to larger Ca2+ influx than other 
neurons (Wilson and Callaway, 2000). 
Several evidences underline the importance of maintaining a correct Ca2+ 
buffering capacity and suggest the perturbations of Ca2+ channels activity as 
responsible for PD associated Ca2+ dyshomeostasis. Indeed, a dramatic 
reduction in the Ca2+ buffering protein calbindin levels has been described in 
brains of PD patients (Iacopino and Christakos, 1990) and dopaminergic 
neurons expressing higher levels of calbindin, or other Ca2+ buffering proteins 
as calretinin and parvalbumin, are resistant to degeneration in PD (Yamada et 
al., 1990; Kim et al., 2000). Furthermore, pharmacological inhibition of 
glutamatergic neurotransmission ameliorates motor abnormalities in 
experimental models of PD (Bonsi et al., 2007) and the administration of 
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dihydropiridine, an L-type channel blocker, confers protection against toxins that 
induce Parkinsonism in experimental animal models (Chan et al.,, 2007). Ca2+ 
dyshomeostasis may be also exacerbated by environmental insults such as 
pesticides, neurotoxins, or inflammation (Mrak and Griffin, 2007). According to 
these findings, rotenone has been shown to induce apoptosis through 
enhanced intracellular Ca2+ influx that can be blocked by nifedipine, a voltage-
gated Ca2+channel-inhibitor (Wang and Xu, 2005). Dopamine itself appears to 
affect the activity of Ca2+ channels in neurons and PC12 cells (Missale et al., 
1998), and recently, it has been proposed that the dopamine metabolism 
induces Ca2+ signaling in astrocytes by stimulating phospholipase C and 
subsequent release of Ca2+ from the ER (Vaarmann et al., 2010). 
The control of sustained Ca2+ transients, in addition to need the action of 
Ca2+ buffering proteins, requires functional mitochondria. Mitochondria directly 
participate in the buffering action, but they are also largely responsible in 
producing ATP indispensable for the action of the active Ca2+ transport systems. 
In addition to the aforementioned considerations, further support for a Ca2+ 
dyshomeostasis link in PD comes from the rapidly expanding literature on 
genetic mutation associated with familial forms of PD. Few papers have started 
to explore the possibility of Ca2+ handling by the PD-related proteins. As matter 
of fact, DJ-1 is a multifunctional protein and, despite its predominant role as 
antioxidant (Taira et al., 2004), it has been shown essential to maintain cytosolic 
basal Ca2+ concentration values and to permit depolarization-induced Ca2+ 
release from the sarcoplasmic reticulum in muscle cells (Shtifman et al., 2011) 
as well as to protect dopaminergic neurons by Ca2+-induced mitochondrial 
uncoupling and ROS production during physiologic pace making (Guzman et 
al., 2010). An augmented phospholipase C activity with consequent increase of 
cytosolic basal Ca2+ concentration and increased vulnerability to 6-
hydroxydopamine (6-OHDA) have also been shown in parkin-deficient human 
neuroblastoma cells (Sandebring et al., 2009). 
More compelling evidences come from studies on α-syn and PINK1. α-Syn 
dependent modulation of Ca2+ influx from the extracellular milieu has been 
described suggesting that the α-syn oligomers could enhance the plasma 
membrane ion permeability (Danzer et al., 2007) either through their direct 
insertion into the plasmamembrane and/or the formation of a pore (Lashuel et 
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al.,, 2002) or through the modulation of plasma membrane Ca2+ permeability 
(Furukawa et al., 2006). However, the link with the pathogenesis is still missing 
and controversial as it has been reported that PD-related α-syn mutants, 
characterized by an enhanced aggregation propensity, play a minor role in 
intracellular Ca2+ increase (Danzer et al., 2007) but also that A53T mutant 
oligomers may increase the plasma membrane Ca2+ permeability (Furukawa et 
al., 2006). The mechanisms through which α-syn aggregation and Ca2+ 
dysfunction influence each other are not clear, but interestingly a functional 
interplay has been reported: intracellular Ca2+ increase promotes α-syn 
aggregation, that in turn could promote intracellular Ca2+ increase. Recent 
studies have shown that α-syn can be associated to mitochondria and that its 
accumulation was directly related to an increase of intramitochondrial Ca2+ 
levels (Parihar et al., 2008), which in turn led to a raise of nitric oxide levels, 
oxidative damage, and cytochrome c release (Parihar et al., 2009), supporting 
the idea of a major role of α-syn in modulating not only the cellular but also the 
mitochondrial Ca2+ fluxes. However, these observations were not constantly 
reported as other studies showed no changes in cellular Ca2+ homeostasis 
following overexpression of WT or mutant α-syn (Hettiarachchi et al., 2009). As 
to PINK1, its direct role in regulating cellular, and most specifically mitochondrial 
Ca2+ fluxes, has been recently proposed starting by the seminal observation that 
the coexpression of mutant, but not WT, PINK1 in a cellular model of PD 
expressing mutated A53T α-syn exacerbated the observed mitochondrial 
defects leading to loss of mitochondrial membrane potential, increased 
mitochondrial size with loss of cristae and reduced ATP levels. The proposed 
mechanisms of PINK1 action was based on a dysregulation of mitochondrial 
Ca2+ influx, as by blocking mitochondrial Ca2+ uptake it was possible to restore 
the original phenotype (Marongiu et al., 2009), thus suggesting that mutant 
PINK1 could reinforce α-syn pathology by acting on converging pathways 
affecting mitochondrial function. 
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1.2.3 Role of alpha synuclein in pathogenesis of Parkinson’s Disease 
 
α-syn is a 140 amino-acid protein that was originally identiﬁed in 
association with synaptic vesicles in the presynaptic nerve terminal (Maroteaux 
et al., 1988) and has been shown to interact with membranes both in vitro and 
in vivo (Davidson et al., 1998; Jo et al., 2000; Fortin et al., 2004). It is highly 
abundant in the brain and also present in other tissues including red blood cells 
(Jakes et al., 1994; Iwai et al., 1995; Nakai et al., 2007; Barbour et al., 2008). α-
syn is a member of a protein family of synucleins, together with beta (β)-and 
gamma (γ)-synuclein. These proteins share a characteristic consensus 
sequence (KTKEGV) that is repeated about six times at the N-terminal part of 
the protein. β-synuclein shares the closest homology (90% homology in the N-
terminus and 33% homology in the C-terminus) with α-syn (Jakes et al., 1994).  
Point mutations in the SNCA gene, encoding for α-syn, and multiplications 
of the SNCA locus have been identiﬁed in families with autosomal-dominant 
forms of PD (Hardy et al., 2009). Genome-wide association studies linked 
single-nucleotide polymorphisms in the SNCA gene with increased susceptibility 
to sporadic PD (Nalls et al., 2011). Moreover, SNCA gene polymorphisms have 
also been associated with increased risk of multiple system atrophy (MSA) 
(Scholz et al., 2009). 
In PD, α-syn is found as a major component of Lewy bodies and Lewy 
neurites, the hallmark protein inclusions made up primarily of insoluble and 
ﬁbrillar α-syn protein (Spillantini et al., 1998a). α-syn also accumulates in 
dementia with Lewy bodies (DLB) and MSA (Spillantini et al., 1998b). In MSA, 
α-syn is found predominantly within oligodendrocytes as cytoplasmic inclusions 
(Wenning and Gesser, 2003). These disorders share the accumulation of α-syn 
aggregates, as a pathological feature and are collectively known as 
synucleinopathies. Additionally, α-syn was also identified as a component of 
amyloid from brain tissues of Alzheimer’s disease (AD) patients (Ueda et al., 
1993). 
The presence of a hydrophobic 12 amino-acid sequence in the central part 
of the protein is required for the oligomerization and ﬁbrillization of α-syn 
(Giasson et al., 2001). Deletion or disruption of this domain blocks the capacity 
of α-syn to form amyloid ﬁbrils. The process of α-syn aggregation (Figure 1) has 
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been studied in detail in an attempt to identify the toxic species responsible for 
neuronal dysfunction and death. However, it is still unclear what is/are the toxic 
forms of the protein. There is evidence showing that inhibition of α-syn 
aggregation process is associated with a decrease of α-syn toxicity (Hashimoto 
et al., 2001; Periquet et al., 2007). However, similarly to the case of amyloid-
beta (Aβ) plaques in AD, it was suggested that the ﬁbrillar forms of α-syn might 
not represent the most toxic α-syn species. Instead, pre-ﬁbrillar, soluble 
oligomeric species (comprising multiple α-syn molecules) are now suggested to 
be the main toxic α-syn species, with amyloid aggregates possibly serving as a 
reservoir for these oligomeric species. In vitro studies showed that the 
acceleration of oligomerisation, and not ﬁbrilization, is the distinctive shared 
property of the A53T and A30P α-syn mutations linked to early-onset PD 
(Conway et al., 2000). The neurotoxic effects of α-syn oligomers were also 
studied in vivo, using animal models of synucleinopathies. In these studies, α-
syn mutant variants that promote oligomer formation were designed and tested 
for toxicity in vivo. On the other hand, in C. elegans and Drosophila models the 
overexpression of α-syn variants with impaired capacity to form ﬁbril caused 
increased toxicity (Karpinar et al., 2009). Similarly, the inability of the mutants to 
form ﬁbrils was directly correlated with toxicity and neurodegeneration (Karpinar 
et al., 2009). In another study, α-syn variants that were shown to promote 
oligomer formation caused most prominent dopaminergic cell death upon 
lentiviral injection into rat substantia nigra (SN) (Winner et al., 2011). Together, 
these studies provide evidence for the importance of soluble oligomers as the 
prominent toxic species in synucleinopathies, although the precise size and 
type of the toxic oligomeric species remains to be determined. 
 
Figure 1.Schematic representation of the α-syn aggregation process. Monomeric forms of α-syn 
associate to form dimers and oligomers that grows into protofibrils and, finally, form mature 
fibrillar strutucters (Marques and Outeiro, 2012). 
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Recently, it was hypothesized that PD, as well as other neurodegenerative 
disorders associated with protein misfolding and aggregation, might be a prion-
like disease where pathological forms of α-syn spread throughout the brain. In 
particular, the spreading of α-syn pathology could contribute to the progression 
of neurodegeneration and clinical symptoms (Braak et al., 2003; Li et al., 2008; 
Hansen et al., 2011). 
The mechanisms that underlie the aberrant functions of α-synuclein and 
how these impacts on disease pathogenesis remain poorly understood, but 
some possibilities have been suggested. 
Data largely derived from α-syn knockout mice suggest that α-syn normally 
mediates negative control of neurotransmitter release and has a possible role in 
assembly of SNARE (Soluble N-ethylmaleimide-sensitive factor attachment 
protein receptor) family complexes (Burre et al., 2010; Abeliovich et al., 2000; 
Larsen et al., 2006; Chandra et al., 2005). Whether these apparently 
physiological functions at the presynaptic terminal contribute to the pathogenic  
effects of α-synuclein has been investigated. It was described an abnormal 
localization of the protein at presynaptic terminals (Iwai et al., 1995). It is 
believed that this accumulation leads to the synaptic dysfunction associated 
with amyloid plaques. In the brains of patients with dementia with Lewy bodies, 
α-synuclein aggregates were located at presynaptic terminals and resulted in 
severe synaptic pathology, leading to almost complete loss of dendritic spines 
at the postsynaptic area (Kramer et al., 2007). As far as α-Syn role in 
neurotransmitter release it has been reported that slight increases in α-syn, 
inhibited neuroansmitter release in glutamatergic hippocampal pyramidal and 
dopaminergic mesencephalic neurons, potentially by a reduction in the pool of 
readily releasable synaptic vesicles (Nemani et al., 2010). In another study, 
overexpression of α-syn in cultured neurons was associated with low 
concentrations of several critical presynaptic proteins involved in exocytosis and 
endocytosis (Scott et al., 2010) and substantial reductions in the frequency of 
excitatory postsynaptic currents, diminished exocytosis, and altered vesicular 
size. A different perspective was provided by a study in another model, in which 
α-syn with C-terminal truncation was transgenically expressed in mouse nigral 
dopaminergic neurons. Functional deﬁcits were related to severe reductions in 
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dopamine release, which were in turn probably due to redistribution, but not 
loss, of presynaptic proteins (Garcia-Reitbock et al., 2010). 
The role of α-syn in neurotransmitter release is mainly based on its 
regulation of synaptic vesicle recycling. α-syn knockout mice display altered DA 
release in response to paired stimuli, reduction in striatal DA and an attenuation 
of DA locomotor response to amphetamine (Abeliovich et al., 2000). Another in 
vivo study showed that lack of α-syn leads to a permanent increase of the 
vesicle reﬁlling rate in the DA readily releasable pool, maintaining stable DA 
release during stimulation in contrast to decline of DA release observed in 
normal conditions (Yavich et al., 2004). Together, these ﬁndings suggest that α-
syn is an activity-dependent, negative regulator of DA neurotransmission. 
A prevailing hypothesis suggests that oligomeric species of α-syn can 
promote the formation of ion-permeable pores on membranes and alter cellular 
homoeostasis (Lashuel et al., 2002; Volles et al., 2001). Increased Ca2+ inﬂux is 
thought to be the main resulting toxic effect (Danzer et al., 2007; Kostka et al., 
2008; Tsigelny et al., 2007; Kayed et al., 2004; Hettiarachchi et al., 2009), and 
could be further augmented via glutamate AMPA receptors (Huls et al., 2011).  
Catecholaminergic neurons might be especially vulnerable to oscillations in 
Ca2+ concentrations because L-type voltage-gated calcium (Cav1.3) channels 
help to maintain their spontaneous pacemaker activity (Chan et al., 2007). 
Although neurons might compensate for high cytosolic concentrations of free 
Ca2+ through a functional sarcoendoplasmic reticulum pump, this system is 
thought to break down in conditions of energy depletion or oxidative stress, 
which might be caused by mitochondrial dysfunction in PD (Chan et al., 2009; 
Guzman et al., 2010). The same pore-forming mechanism is thought to enable 
oligomeric α-syn to attack synaptic vesicles, which leads to leakage of 
neurotransmitter into the cytosol: for dopamine, high cytosolic concentrations 
could lead to oxidative stress, intracellular interactions between Ca2+, 
dopamine, and α-syn, and the triggering of a neurodegenerative cascade 
(Mosharov et al., 2006). Another contributing factor could be calcium-mediated 
activation of calpains, which might lead to C-terminal truncation and 
oligomerisation of α-synuclein, (Mishizen-Eberz et al., 2005) further Ca2+ inﬂux, 
and neurotoxic effects. 
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1.3 Sodium Calcium Exchanger 
 
The Na+/Ca2+ exchanger (NCX) represents a major transporter assuring 
Ca2+ efflux from mammalian cells (Blaustein and Lederer, 1999). Under 
physiologic conditions NCX is a ubiquitous mechanism providing the exchange 
of 3Na+/1Ca2+ between cytoplasm and extracellular medium. In most tissues, it 
operates in a “forward” way corresponding to inward current and thus to calcium 
exit from the cell (Blaustein and Lederer, 1999). Under some conditions, 
however, a reverse mode of Na+ /Ca2+ exchange can be activated coupling the 
extrusion of three Na+ ions with the influx of one Ca2+ ion (Blaustein and 
Lederer, 1999; Philipson and Nicoll, 2000; Annunziato et al., 2004). 
NCX proteins consist of nine transmembrane segments (TMSs) with a 
large cytoplasmic f-loop between TMSs 5 and 6 composed of two adjacent Ca2+ 
-binding domains, CBD1 and CBD2 (Philipson and Nicoll, 2000; Levitsky et al., 
1994; Hilge et al., 2006). Two CBD domains are connected through a short 
linker to form a “head-to-tail”-oriented two-domain tandem, CBD1/2 (Hilge et al., 
2006, 2009). Allosteric regulation of NCX requires Ca2+ to interact with the CBD 
domains (Weber et al., 2001; Nicoll et al., 2007; Reeves and Condrescu, 2008; 
Boyman et al., 2011) (Fig. 2). 
 
Figure 2.Schematic representation of the sodium calcium exchanger (NCX) (Modified from 
Iwamoto et al., 2004). 
 
NCX belongs to a multigene family comprising three isoforms, named 
NCX1, NCX2, and NCX3. To fulﬁll the physiological demands of various cell 
types, the Na+/Ca2+exchanger isoforms and their splice variants are expressed 
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in a tissue-speciﬁc manner (Philipson and Nicoll, 2000; Lytton, 2007; 
Khananshvili, 2012). NCX1 is ubiquitously expressed in all tissues, NCX2 is 
mainly restricted to the brain, and NCX3 is expressed exclusively in brain and 
skeletal muscles (Quednau et al., 1997). In addition, NCX1 and NCX3 give rise 
to several splicing variants that appear to be selectively expressed in different 
regions and cellular populations of the brain (Quednau et al., 1997; Yu and 
Colvin, 1997). In fact, NCX1 mRNA can be detected in midbrain and in basal 
ganglia in which dopaminergic cell bodies are localized. Moreover, NCX1 
protein isoform is present in the striatum, where the terminal projection fields of 
dopaminergic nigrostriatal neurons are found (Canitano et al., 2002; Papa et al., 
2003). 
Several factors are involved in the regulation of NCX activity. Among them, 
the two transported ions; Na+ and Ca2+ play a crucial role. Indeed, a rise in 
cytosolic [Na+] rapidly stimulates and then inactivates the exchanger, whereas a 
rise in cytosolic [Ca2+] activates NCX and relieves the Na+-dependent 
inactivation (Hilgemann et al., 1992a, b). Moreover, NCX is extremely sensitive 
to cytosolic acidiﬁcation, redox status and metabolic state (DiPolo and Beauge, 
1982, 2006; Doering and Lederer, 1994; Doering et al., 1996). These factors 
imply, in some cases, modiﬁcations of the exchange activity and, in others, 
alterations of the protein expression and docking into the membrane where, 
associated with other transporters such as Na+/K+-ATPase and Na+/H+ 
exchanger as well as enzymes like kinases and phosphatases, they form 
functional supra molecular complexes (Bers and Despa, 2009; Schulze et al., 
2003; Hilgemann, 2007; McLaughlin et al., 2002; Berberián et al., 2009).    
The activity of NCX is important especially in some neurophysiological 
conditions. In fact, the level of expression of NCX in neurons is predominantly 
high in those sites where a large movement of Ca2+ ions occurs across the 
plasma membrane, as it happens at the level of synapses (Juhaszova et al., 
1996; Canitano et al., 2002). Specifically, during an action potential or after 
glutamate-activated channel activity, Ca2+ massively enters the plasma 
membrane. Such phenomenon triggers the fusion of synaptic vesicles with the 
plasmamembrane and promotes neurotransmitter exocytosis. After this event, 
outward K+ currents repolarize the plasma membrane, thus leading to voltage 
gated calcium channels closure. According to the diffusion principle, Ca2+ ions 
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are distributed in the cytosolic compartment, reversibly interacting with Ca2+-
binding proteins. Residual Ca2+ ions are then rapidly extruded by the plasma 
membrane Ca2+ ATPase and by NCX activation. The Na+/Ca2+exchanger 
becomes the dominant Ca2+ extrusion mechanism when [Ca2+]I is higher than 
500nM, as it happens when a train of action potentials reaches the nerve 
terminals. It has been calculated that for these [Ca2+]i  values, more than 60% of 
Ca2+ extrusion is mediated by Na+/Ca2+exchanger families. In such 
physiological conditions, NCX activation is consistent with its low-affinity (Kd 
500nM) and high-capacity (5x103Ca2+/s) function. In contrast, in resting 
conditions or after a single action potential, when [Ca2+]i slightly increases, 
requiring, therefore, a more subtle control, the high-affinity (Kd100 nM) and low-
capacity (102Ca2+/s) pump, the plasmamembrane Ca2+ATPase, assumes a 
predominant function, thus making the involvement of NCX less relevant 
(Blaustein and Lederer, 1999). 
On the other hand, dysregulation of [Ca2+]i and [Na
+]i homeostasis is 
involved in neuronal injury occurring in in vitro and in vivo models of hypoxia-
anoxia and in several neurodegenerative diseases. More specifically, in the 
early phase of neuronal anoxic insult, the Na+/K+-ATPase blockade increases 
[Na+]i, which in turn induces NCX to reverse its mode of operation. Although 
during this phase NCX causes an increase in [Ca2+]i, its effect on neurons 
appears beneficial for two reasons. First, by promoting Ca2+ influx, NCX 
promotes Ca2+ refilling into the ER, which is depleted by anoxia followed by 
reoxygenation, thus allowing neurons to delay ER stress (Sirabella et al., 2009). 
Second, by eliciting the decrease in [Na+]i overload, NCX prevents cell swelling 
and death (Annunziato et al., 2007). Conversely, in the later phase of neuronal 
anoxia, when [Ca2+]i overload takes place, NCX forward mode of operation 
contributes to the lowering of [Ca2+]i, thus protecting neurons from [Ca
2+]i-
induced neurotoxicity (Annunziato et al., 2004). Moreover, further studies have 
demonstrated that BHK cells overexpressing NCX1 or NCX3 isoforms are more 
vulnerable to chemical hypoxia compared to BHK cells expressing NCX3 
isoforms, thus suggesting that each of the three isoforms has different 
functional properties and might play a different role in the pathogenesis of a 
cellular damage  (Secondo et al., 2007; Bano et al., 2005). Another study shows 
that ischemic rats treated with NCX1 or NCX3 antisense display a remarkable 
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enlargement of the infarct volume (Pignataro et al., 2004) thus suggesting a 
crucial role of these two isoforms in the pathogenesis of ischemic damage. 
It is also demonstrated that NCX plays an important role during aging, 
since the impairment of Ca2+homeostasis in neuronal cells is considered to be 
the major triggering event that leads to the development of brain aging 
(Annunziato et al., 2002). Studies performed on the cerebro-cortex nerve 
endings of aged rats have shown that the activity of NCX is markedly reduced in 
the forward and in the reverse mode of action (Michaelis et al., 1984; 
Canzoniero et al., 1992). NCX decline seems to be the consequence of a 
reduced affinity of the antiporter for Ca2+ions (Michaelis et al., 1984).  
In this sense, during aging and also during neurodegenerative diseases, 
such as Alzheimer’s disease and Parkinson’s disease in which a neuronal 
calcium dysfunction is found, NCX might have a relevant role. In fact, a study 
performed in the synaptic terminals obtained from the brain cortex of AD 
patients showed that NCX activity was increased (Colvin et al., 1994). Another 
study performed in synaptosomes prepared from cryopreserved brain of 
cognitively normal aged controls and late stage Alzheimer's disease patients 
demonstrated that NCX2 protein expression was upregulated whereas, NCX3 
native 105 kDa band was downregulated (Sokolow et al., 2011). Moreover, 
NCX1, NCX2, and NCX3 colocalize with Aβ in synaptic terminals (Sokolow et 
al., 2011). On the other hand, it is important to underline the role played by the 
mitochondrial sodium calcium exchanger (NCXmito) during neurodegeneration 
with particular regard to Parkinson Diseases (Castaldo et al., 2009). Indeed, it 
has been reported that during Parkinson’s disease the activation of NCXmito is 
the primary mechanism by which mitochondrial calcium concentrations [Ca2+]m 
is returned to the cytoplasm and therefore it is critical to a multitude of Ca2+-
dependent processes including neurotransmitter release, synaptic plasticity, 
bioenergetics and mitochondrial NO and free radical generation (Castaldo et al., 
2009). Recently, It was found that in the absence of PINK1, NCX
mito 
activity was 
severely impaired, leading to mitochondrial calcium overload, permeability 
transition pore opening and cell death (Gandhi et al., 2009). It was proposed 
that NCXmito is entirely distinct from the characterized plasmalemmal NCX 
isoforms, due the specific sensitivity of NCXmito to the inhibitor CGP-37157 
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(Czyz and Kiedrowski, 2003).  Recently, it has been shown that among the 
three isoforms of NCX, the NCX3 isoform is the only one detected on the outer 
mitochondrial membrane where it plays an important role in cell survival during 
hypoxia (Scorziello et al., 2013). Moreover, a recent study showed that the 
plasmalemal NCX2 and NCX3 contribute to mitochondrial Na+/Ca2+exchange in 
human DA neurons and may act downstream of PINK1 in the prevention of 
neurodegeneration by [Ca2+]m accumulation (Wood-Kaczmar et al.,, 2013).  
These studies have potentially revealed a new molecular target in Parkinson’s 
disease pathologenesis, which ultimately may open up new avenues for future 
therapeutic intervention. 
 
1.4 Experimental models for Parkinson’s disease 
1.4.1 In vitro models 
 
Over the last two decades significant advances have been made to 
improve the knowledge of both the etiology and pathogenesis of PD. 
Experimental models are of paramount importance to obtain greater insights 
into the pathogenesis of the disease (Bezard et al., 2013). In this sense, great 
progresses have been made in the experimental studies of PD, especially 
through the use of cellular models. The development of a stable and reliable 
dopaminergic neuronal cell model is particularly necessary for studying the 
pathogenesis of PD and developing therapeutic strategies. An ideal in vitro PD 
cellular model should be established in post-mitotic human dopaminergic 
neuronal cells susceptible to neurotoxins produced during PD so as to address 
questions regarding the selective loss of DA neurons in the substantia nigra. 
Presently, PD cell models primarily include non-neuronal tumor cell lines such 
as pheochromocytoma, PC12, cells (Koch et al., 2009),
 
neuronal tumor cell 
lines represented by human neuroblastoma SH-SY5Y, cells (Cheng et al., 
2009)
 
and primary mesencephalic neurons (Takeuchi et al., 2009).
 
The 
treatment of these cells with neurotoxins such as 1-methyl-4-phenyl-pyridinium 
(MPP+), 6-hydroxydopamine (6-OHDA), or rotenone mimics many aspects of 
the dopaminergic neuronal death observed in PD. Since these neurotoxins are 
unsuitable for systemic administration because they do not cross the blood-
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brain barrier (BBB), they are more useful in neuronal cultures. These models 
are suitable for studying detailed mechanisms of dopaminergic neuronal 
degeneration and for screening new pharmacological agents (Kitamura et al., 
1998; Sawada et al., 1996). Other less often utilized neurotoxins are rotenone, 
paraquat, isoquinoline derivatives and methamphetamine (Bezard and 
Przedborski, 2011).  
The noradrenergic analogue 6-OHDA and several other synthesized 
analogues have been introduced as catecholaminergic neurotoxins over 30 
years ago (Jonsson and Kasamatsu, 1983). Since then, these neurotoxins have 
been extensively used for both in vitro and in vivo investigations. In particular, 6-
OHDA shares some structural similarities with dopamine and norepinephrine, 
exhibiting a high affinity for several catecholaminergic plasma membrane 
transporters such as the dopamine (DAT) and norepinephrine transporters 
(NET). Consequently, 6-OHDA can enter both dopaminergic and noradrenergic 
neurons and inflict damage to the catecholaminergic pathways of both the 
peripheral and the central nervous systems (Jonsson, 1983; Jonsson, 1980). 
With respect to its mode of action, it is well accepted that 6-OHDA destroys 
catecholaminergic structures by a combined effect of reactive oxygen species 
(ROS) and quinones (Cohen, 1984). This view stems primarily from the 
demonstration that 6-OHDA once dissolved in an aerobic and alkaline milieu 
readily oxidizes, yielding hydrogen peroxide (H2O2) and para-quinone (Saner et 
al., 1971 Heikkila and Cohen, 1971). However, 6-OHDA lesions do not result in 
Lewy body formation in the substantia nigra, and can cause nonspecific 
damage to other neurons (Shimohama et al., 2003). 
Another neurotoxin administered in in vivo and in vitro models for 
Parkinson’s disease is the mitochondrial electron transport chain complex I 
inhibitor MPTP. This toxin is converted to MPP+, which is taken up via the DA 
transporter and accumulates in dopaminergic neurons. Absorbed MPP+ 
concentrates in mitochondria, where it inhibits complex I of the electron 
transport chain, thereby reducing ATP generation and causing the production of 
reactive oxygen species (ROS) with consequent apoptotic death of 
dopaminergic neurons (Kitamura et al., 2000, 2003; Speciale, 2002). Moreover, 
MPTP-induced toxicity is often presented as being “specific” for the dopamine 
neurons, although it is well known that MPTP induces multisystemic lesions 
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(Bezard et al., 2013). 
Among the toxic models of PD, rotenone represents one of the most 
recently used approaches (Betarbet et al., 2000). Rotenone is the most potent 
member of the rotenoids, a family of natural cytotoxic compounds extracted 
from various parts of Leguminosa plants. Rotenone is widely used around the 
world as insecticide and pesticide (Hisata, 2002). Because of its short half-life 
and because it does not readily leach from soil, it is not expected to be a 
groundwater pollutant. Consequently, the likelihood that PD might be caused by 
an environmental exposure to rotenone is low. Conversely, it must be 
remembered that many environmental neurotoxins other than rotenone have a 
long half-life. Thus, if rotenone appears an unlikely culprit, several others could 
account for the epidemiological data showing that the risk of PD increases with 
exposure to pesticides (Butterﬁeld et al., 1993; Gorell et al., 1998).  
Like MPTP, rotenone is highly lipophilic and thus readily gains access to 
all organs including the brain. After a single intravenous and/or intrastriatal 
injection, rotenone reaches maximal concentration in the central nervous 
system within 15 min and decays to about half of this level in less than 2h 
(Talpade et al., 2000). Its brain distribution is heterogeneous (Talpade et al., 
2000). Rotenone also freely crosses all cellular membranes and can 
accumulate in subcellular organelles such as mitochondria. In mitochondria, 
rotenone impairs oxidative phosphorylation by inhibiting reduced Nicotinamide 
Adenine Dinucleotide (NADH)-ubiquinone reductase activity through its binding 
to the PSST (20kDA subunit of complex 1) subunit of the multipolypeptide 
enzyme complex I of the electron transport chain (Schuler and Casida, 2001). 
Aside from its action on mitochondrial respiration, rotenone also inhibits the 
formation of microtubules from tubulin (Marshall and Himes, 1978; Brinkley et 
al., 1974). This effect may be quite relevant to the mechanism of dopaminergic 
neurodegeneration because excess of tubulin monomers may be toxic to cells 
(Burke et al., 1989; Weinstein and Solomon, 1990). Interestingly, a protein 
implicated in some familial forms of PD, parkin, appears to bind to tubulin, 
thereby enhancing the ubiquitination and degradation of misfolded tubulins, an 
effect that is lacking with the PD-linked parkin mutants (Ren et al., 2003). 
Rotenone has been used extensively as a prototypic mitochondrial poison in 
cell cultures, but less frequently in living animals. Exposure of embryonic ventral 
 25 
midbrain cultures to rotenone causes major neurotoxicity (Marey-Semper et al., 
1995), especially in the presence of microglial cells (Gao et al., 2002).  
The potent herbicide paraquat (N,N’-dimethyl-4-4’-bipiridinium) is another 
prototypic toxin known to exert deleterious effects through oxidative stress. 
Indeed, paraquat toxicity is mediated by redox cycling with cellular diaphorase 
such as nitric oxide synthase (Day et al., 1999), yielding ROS. Thus far, there 
have been several cases of lethal poisoning resulting from ingestion or dermal 
exposure (Smith, 1988). For many years, experimental studies using paraquat 
were focused on its effects on lung, liver, and kidney probably because the 
toxicity induced by this herbicide in these organs is responsible for death after 
acute exposure. However, signiﬁcant damage to the brain was seen in 
individuals who died from paraquat intoxication (Grant and Lantos, 1980; 
Hughes, 1988) despite the fact that paraquat poorly crosses the BBB 
spontaneously (Shimizu et al., 2001). Furthermore, epidemiological studies 
have suggested an increased risk for PD due to paraquat exposure (Liou et al., 
1997), raising the possibility that paraquat could be an environmental toxin that 
can provokes Parkinson’s disease. In keeping with this, it is relevant to point out 
that paraquat exhibits a striking structural similarity to MPTP toxic metabolite 
MPP+. Although ROS are incontestably involved in the deleterious mechanism 
by which paraquat kills dopaminergic neurons, the molecular link between 
oxidative stress and cell death in this model remains unknown. It appears, 
however, that paraquat can trigger the sequential activation of c-Jun N-terminal 
kinase (JNK), and caspase-3 both in vitro and in vivo (Peng et al., 2004), 
suggesting that JNK signaling pathways could mediate paraquat-induced 
neurodegeneration. 
 
1.4.2 In vivo models 
 
The brains of PD patients show evidence of impaired mitochondrial 
complex I function and of the generation of oxidative stress and these might, 
therefore, be crucial components of nigral dopaminergic neuronal damage. 
Studies using MPTP, 6-OHDA and rotenone, as mentioned before, have 
provided insights into the molecular mechanisms leading to dopaminergic 
neuronal death (Shimohama et al., 2003). Although the ability of these 
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neurotoxins to induce marked, if not total, and long-lasting lesions of the 
nigrostriatal pathway is widely accepted, their ability to replicate the dorso-
ventral gradient of striatal denervation in PD (Kish et al., 1988; Brooks et al., 
1990) is still a matter of discussion despite clear experimental evidences.  
Indeed, 6-OHDA and also other neurotixins poorly crosses the BBB, hence 
failing to accumulate within the brain parenchyma to meaningful neurotoxic 
concentrations following systemic injections. To circumvent this problem, 6-
OHDA has to be injected directly into the brain either free hand or by stereotaxic 
means. Several local sites of injection have been used to damage the central 
dopaminergic pathways including intraventricular, intracisternal, and 
intracerebral (Jonsson et al., 1983). Discrete intrastriatal administrations of 6-
OHDA in the rat can achieve such replication (Kirik et al., 1998). Striking 
examples of such preferential dorso-ventral striatal denervation have been 
produced with the MPTP in the marmoset (Iravani et al., 2005), the African 
green monkey (Jan et al., 2003) and the macaque monkeys (Bezard et al., 
2001; Guigoni et al., 2005; Moratalla et al., 1992) suggesting that chronic 
exposures consistently allow to mimic the human PD specific pattern of 
nigrostriatal lesion while earlier intracarotid and acute regimen did not. 
Interestingly, various MPTP intoxication regimens are reported to affect α-
synuclein levels and aggregation. Indeed, α-synuclein aggregates have been 
observed in a chronic MPTP model (Fornai et al., 2005). Such phenomenon has 
been better documented in the MPTP monkey models in which a clear 
relationship between dopaminergic cell loss, α-synuclein upregulation, neuritic 
α-synuclein pathology and α-synuclein aggregation has been established 
(McCormack et al., 2010; McCormack et al., 2008; Purisai et al., 2005). 
Interestingly, such changes occurred mostly in neuromelanin-positive neurons 
(Purisai et al., 2005).  
Recent gene-targeting and transgenic strategies have generated several 
mouse lines with mutations in the dopaminergic system (Jankowsky et al., 
2002). Mice that lack the gene encoding Nurr1 (Zetterstrom et al., 1997) or 
tyrosine hydroxylase (Zhou et al., 1995), or are deﬁcient in DA production (Zhou 
and Palmiter, 1995), die at a late embryonic stage or shortly after birth, 
suggesting that DA is essential for embryonic development. By contrast, mice in 
which the D2 receptor is deleted survive, but show decreased spontaneous 
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movement, as with drug-induced Parkinsonism (Baik et al., 1995), and mice that 
lack D1 or D3 receptors show increased locomotor activity (Xu et al., 1994; 
Accili et al., 1996). Thus, D2-receptor-deﬁcient mice exhibit PD-like symptoms 
without neuronal death and Lewy body formation. 
In the last decades, the discovery of familiar mutations in PD patients, like 
mutations in the gene encoding α-synuclein (Vila et al., 2001) has launched a 
series of genetic models to study PD. In this sense, a model of PD by 
expressing mutant and normal forms of α-synuclein in Drosophila was produced 
(Feany et al., 2000). In this model an age-dependent loss of dorsomedial 
neurons positive to TH occurs. However, other subsets of dopaminergic 
neurons showed no abnormalities, consistent with the differential vulnerability of 
dopaminergic neurons in human PD. However, α-synuclein-stained inclusions 
that resembled Lewy bodies have been also observed in neurons, by light 
microscopy and EM. The ﬂies developed locomotor dysfunction with age, and 
this was more apparent in transgenic ﬂies overexpressing A30P-mutant α-
synuclein than in those with A53T-mutant or wild type α-synuclein. 
Nevertheless, transgenic ﬂies fulﬁll most of the criteria for a relevant PD model, 
including progression, age dependence, selective loss of DA neurons and the 
formation of Lewy-body-like inclusions. Because invertebrates have simple 
neuronal networks and motor functions, they might be useful as PD models.  
Additionally, overexpression of human wild type α-synuclein in mice 
(Masliah et al., 2000) led to the formation of cytoplasmic and nuclear 
microinclusions with α-synuclein and ubiquitin, and a reduction in striatal TH 
activity and motor performance. However, wild type α-synuclein mouse was 
natively expressed, and the decrease in TH activity and locomotion were 
relatively low.  Some of the transgenic mice expressing full-length α-synuclein 
with the A53T or A30P mutations show abnormal motor behavior associated 
with granular or filamentous material. However, in some cases these alterations 
appear to be mainly linked to the pathology in the spinal cord and not to a 
dysfunction in the substantia nigra (Giasson et al., 2002; Rieker et al., 2011).  
In the last years, the identification of LRRK2 (Leucine-rich repeat kinase 2) 
mutations as the genetic cause for PARK8 (Familial Parkinson’s disease type 8) 
(Zimprich et al., 2004; Paisan-Ruiz et al., 2004) has triggered another wave of 
PD model generation. LRRK2 encodes a large complex protein consisting of 
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multiple conserved domains such as N-terminal ankyrin repeat, Leucine-rich 
repeat domain, ROC (GTPase) domain, MAPKKK-like kinase domain, and C-
terminal WD40 domain.  At least 6 mutations in LRRK2, G2019S, R1441C/G/H, 
I2020T and Y1699C are believed to be pathogenic. G2019S mutation alone 
accounts for the most common inherited form of PD (Mata et al., 2006; Healy et 
al., 2008) (~4%). In fact, mutations of LRRK2 are also linked to some sporadic 
forms and the clinical symptoms and neuropathology of LRRK2- associated PD 
are indistinguishable from idiopathic PD (Zimprich et al., 2004; Paisan-Ruiz et 
al., 2004). The autosomal dominant transmission of LRRK2 mutations makes 
transgenic expression of pathogenic LRRK2 species suitable for modelling 
disease process in PD. Indeed, various invertebrate transgenic models 
producing LRRK2 PD mutants were quickly reported after the discovery of 
LRRK2 mutations in PD; the phenotypes of the models range from no change to 
apparent neuronal loss or deficits in dopaminergic systems and motor behavior 
(Yue, 2009). Certain lines exhibiting PD-related pathologies were reportedly 
used to evaluate LRRK2 kinase inhibitors in neuroprotection, revealing the 
potential value of the invertebrate LRRK2 models in drug screening (Liu et al., 
2011). These models are useful for understanding early pathogenic events in 
PD. Current evidence suggests that the striatal DA abnormality often precedes 
the frank motor function deficits in G2019S PD patients and perhaps the loss of 
dopaminergic neurons. Therefore, the LRRK2 rodent models may recapitulate 
the specific disease stage that presents an early pathological alteration prior to 
the loss of nigral neurons. Thus, the LRRK2 models can be used to explore the 
interactions between genetic risk and environmental factors that underlie the PD 
etiology (Bezard et al., 2013). 
Therefore, there is no “best model of PD,” as none is a true pathological 
copy of the human condition; these models are only approximations, each 
possibly holding a certain degree of relevance. Thus, to increase the chance of 
fruitful preclinical investigations, it would be useful: first know the strengths and 
the weaknesses of each model, second, select models whose characteristics 
are most suitable for addressing the experimental question, and third, the 
possible application in clinical relevant designs.  
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2. AIM OF THE STUDY 
 
By means of multidisciplinary approaches, from molecular biology and 
biochemistry to confocal microscopy and behavior test, the specific aims of the 
study were: (1) To evaluate the expression of the three isoforms of Na+/Ca2+ 
exchanger (NCX), NCX1, NCX2, NCX3, a plasma membrane protein that plays 
a prominent role in controlling intracellular homeostasis of Ca2+ and Na+ ions, in 
animal and cellular models of PD represented by mutant α-synuclein A53T mice 
and primary neurons obtained from embryos of mutant α-synuclein A53T mice; 
(2) To verify the role of α-synuclein in the modulation of the expression and 
activity of the three isoforms of the Na+/Ca2+ exchanger in A53T mice and in 
primary midbrain neurons; (3) To investigate whether the modulation of the 
Na+/Ca2+ exchanger could  be correlated with the loss of dopaminergic neurons 
in striatum and midbrain of transgenic A53T mice and in primary midbrain 
neurons; (4) To verify whether changes in NCX expression could be correlated 
with an impairment in locomotor activity of mutant α-synuclein A53T mice 
assessed by means of Pole test and Open Field test; (5) To understand the role 
played by each of these three isoforms in the progression of neuronal damage 
with particular regard to mitochondrial dysfunction; (6) To correlate the 
deregulation of intraneuronal Ca2+ ions homeostasis with the mitochondrial 
dysfunction in primary midbrain neurons from mutant α-synuclein A53T mice in 
order to define the temporal and spatial interplay between the two events.  
In order to evaluate whether changes in NCX expression could be 
detected in mutant α-synuclein A53T mice during aging, molecular biology 
experiments were performed in midbrain and in striatum of mutant α-synuclein 
A53T and wild type 4, 10 and 16 months old mice. These experiments identified 
a reduction in protein expression of NCX2 and NCX3 isoforms in midbrain of 
A53T 4 and 10 months old transgenic mice respectively, in comparison to wild 
type mice. Conversely, NCX1 protein expression was increased in A53T 10 
months old transgenic mice in striatum compared to wild type 10 months old 
mice. To correlate these results with the deposition of mutated α-synuclein, the 
expression of this protein was evaluated in WT and transgenic mice during 
aging. The results of these experiments showed that an accumulation of α-
synuclein occurred during aging in both midbrain and striatum of A53T 
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transgenic mice. Moreover, to demonstrate that the alteration in NCX isoforms 
expression followed by an accumulation of α-synuclein might be correlated with 
a loss of dopaminergic neurons observed in PD, tyrosine hydroxylase protein 
expression was evaluated in midbrain and striatum of WT and transgenic mice 
during aging. These experiments demonstrated that dopaminergic neuronal loss 
occurred both in the midbrain of 4 and 10 months old mice and in the striatum of 
A53T transgenic 4, 10 and 16 months old mice. To verify whether the 
biochemical events observed correlate with changes in locomotor activity of 
A53T Tg mice, behavior tests were performed in these mice during aging. 
Locomotor activity was explored by means of Open Field test to evaluate the 
spontaneous activity and the Pole test to evaluate balance and bradykinesia. 
The results obtained by means of the Open Field test showed a decrease in the 
spontaneous motor activity in 16 months old transgenic mice, since they spent 
more time on longer rest during their exploration in the arena in comparison to 
wild type mice at the same age. Pole test was used to evaluate the imbalance 
and bradykinesia in this mouse model. Accordingly, mice were placed head 
upward on the top of a pole and the time spent to climb down to the pole until to 
the floor was recorded. The results obtained showed an impairment in motor 
activity during aging in transgenic mice. Indeed they took more time to climb 
down to the pole compared to wild type mice. 
 Parallel experiments were performed in vitro in primary midbrain neurons 
obtained from A53T transgenic mice embryos and in the respective wild type in 
which western blot experiments were performed to evaluate the modulation of 
NCX isoforms. The results of these experiments demonstrated that among the 
three isoforms, only NCX3 protein expression was reduced in A53T transgenic 
neurons. In addition, TH protein expression was also reduced in primary 
midbrain neuronal culture. Since NCX plays an important role in cellular calcium 
homeostasis and NCX3 is also localized on the outer mitochondrial membrane 
(Scorziello et al., 2013) its role in the regulation of in mitochondrial and cytosolic 
calcium concentrations was explored in primary midbrain neurons from embryos 
of mutant α-synuclein A53T and wild type mice by means of confocal 
microscopy techniques. The results obtained showed an increase in cytosolic 
calcium concentrations of A53T transgenic neurons compared to wild type. This 
 31 
effect was associated with an increase in mitochondrial calcium concentration 
and of mitochondrial membrane hyperpolarization.  
In conclusion the overall results described let to hypothesize a possible 
involvement of NCX1 and NCX3 in the degeneration of dopaminergic neurons 
in A53T transgenic mice probably associated with accumulation of -synuclein, 
thus suggesting the identification of new molecular targets in the pathogenesis 
of PD. 
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3. EXPERIMENTAL PROCEDURES 
 
3.1  In vivo and in vitro models 
3.1.1. Transgenic mice for α-synuclein (A53T) 
 
Mice that express human A53T α-syn under the control of prion promoter 
(Pmp-SNCA*A53T) (Giasson et al., 2002) were obtained from The Jackson 
Laboratory. Mice hemizygous for the A53T mutation were bred on a mixed 
C57Bl/6 x C3H background to produce transgenic and non-transgenic 
littermates. In all cases, 4, 10, 16-months old transgenic mice were directly 
compared with age-matched wild type littermates. To identify transgenic mice 
PCR amplifications were performed according to the protocol from The Jackson 
Laboratory. Mice were group housed (1-5 animals/cage) in temperature and 
humidity-controlled rooms under a 12-hours light-/dark cycle and fed ad libitum 
diet of standard mouse chow. Experiments were performed on male and female 
mice according to the international guidelines for animal research and approved 
by the Animal Care Committee of “Federico II” University of Naples, Italy.    
 
3.1.2. Primary midbrain neurons from transgenic mice for α-synuclein (A53T) 
 
Primary midbrain cultures were isolated from brains of 15 days-old A53T 
and wild type mice embryos, were prepared by modifying the previously 
described method of Fath and collaborators (Fath et al., 2009). The tissue was 
minced and incubated with a dissection medium containing MEM, NaHCO3 and 
Dextrose for 30 minutes at 37°C. After incubation, the suspension was 
centrifuged and subjected to mechanical dissection in order to obtain a cellular 
suspension. Then the cells were placed on poly-D-lysine-coated (100µg/ml) 
plastic dishes, in MEM/F12 culture medium containing glucose, 5% deactivated 
fetal bovine serum, and 5% horse serum, glutamine (2mM), penicillin (50 U/ml), 
streptomycin (50 μg/ml). For confocal and calcium imaging experiments, cells 
were plated on glass coverslips coated with poly-D-lysine (Scorziello et al., 
2007). The day after plating, cells were treated with Cytosine- D-arabino-
furanoside in vitro (10 μM) to prevent the non-neuronal cell growth. Neurons 
 33 
were cultured at 37°C in a humidified 5% CO2 atmosphere and used after 10 
days of the culture for all experiments described.   
 
3.2 Western Blot Analysis 
 
Mice brain tissue and primary neurons were lysed in a buffer containing 
Tris-HCl (20 mM, pH 7.5); NaF 10 mM; NaCl 150 mM; phenylmethylsulphonyl 
fluoride (PMSF) 1 mM; NONIDET P-40 1%; Na3VO4 1 mM; aprotinin 0.1%; 
pepstatin 0.7 mg/ml e leupeptin 1 μg/ml. Homogenates were centrifuged at 
14.000 rpm for 20 minutes at 4ºC. Supernatant was used to perform western 
blot analysis. Protein levels were determined using Bradford method. The total 
protein used for each sample was 50μg and it was separated on 8% sodium 
dodecyl sulfate polyacrylamide gels with 5% sodium dodecyl sulphate stacking 
gel (SDS-PAGE) and transferred to nitrocellulose membranes. The membranes 
were blocked in 5% non-fat dry milk in 0,1% Tween 20 (TBS-T; 2mmol/l Tris 
HCl, 50mmol/l NaCl, pH 7,5) for 1 hour at room temperature and incubated 
overnight at 4ºC in the blocked buffer with the 1:5000 antibody for NCX1 
(polyclonal mouse antibody), 1:1000 antibody for NCX2 (polyclonal rabbit 
antibody), 1:5000 antibody for NCX3 (polyclonal rabbit antibody), 1:1000 for α-
synuclein (monoclonal rabbit antibody) and 1:10000 for Tyrosine Hydroxylase 
(monoclonal mouse antibody). Next, all membranes were washed 3 times with a 
solution containing Tween 20 (0,1%) and subsequently incubated with the 
secondary antibodies for 1 hour (1:2000) at room temperature.  The 
immunoreactive bands were visualized by enhance chemiluminescence. The 
optical density of the bands (normalized with those of tubulin) was determined 
by Image J program. 
 
3.3 Mitochondrial calcium concentrations [Ca2+]m, cytosolic calcium 
concentrations [Ca2+]c  and mitochondrial membrane potential 
measurements 
 
To assess the [Ca2+]m, neurons obtained from embryo A53T and wild type 
mice were loaded with X-Rhod-1 (0.2 μM) for 15 min in a medium containing 
156mM NaCl, 3mM KCl, 2mM MgSO4, 1.25mM KH2PO4, 2mM CaCl2, 10mM 
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glucose, and 10mM Hepes. The pH was adjusted to 7.35 with NaOH. At the end 
of the incubation, cells were washed 3 times in the same medium. An increase 
in mitochondria-localized intensity of fluorescence was indicative of 
mitochondria Ca2+ overload (Sisalli et al., 2014). 
[Ca2+]c was measured  using the fluorescent dye Fluo-3AM acetixymethyl 
ester (Fluo-3AM). Cells were loaded with Fluo-3AM (5 nM) for 30 min at room 
temperature in the same medium described above. At the end of incubation, 
cells were washed 3 times in the same medium. An increase in [Ca2+]c intensity 
of fluorescence was indicative of cytosolic Ca2+ overload (Secondo et al., 2007).  
Mitochondrial membrane potential was evaluated using the fluorescent 
dye tetramethyl rhodamine ethyl ester (TMRE) in the “redistribution mode”. 
Cells were loaded with TMRE (20nM) for 30 minutes in the above described 
medium. At the end of the incubation, cells were washed in the same medium 
containing TMRE (20nM) and allowed to equilibrate (Livigni et al., 2006). A 
decline in mitochondria-localized intensity of fluorescence was indicative of 
mitochondrial membrane depolarization. 
Confocal images were obtained using Zeiss inverted 510 confocal laser 
scanning microscopy and a 63X oil immersion objective. The illumination 
intensity of 543 Xenon laser used to excite X-Rhod-1 and TMRE, and of 488 
Argon laser used to excite Fluo-3AM fluorescence, was kept to a minimum of 
0.5% of laser output to avoid phototoxicity. 
 
3.4 Evaluation of locomotor activity     
3.4.1 Open Field Test 
 
Spontaneous exploratory locomotor behavior was evaluated by means of 
the Open Field test. The Open Field test presents an appropriate paradigm for 
the phenotyping characterization of transgenic mice (Hinkle et al., 2012). The 
test has been successfully used with other familial Parkinson disease mouse 
models, for example mice deficient in parkin gene (Zhu et al., 2007). The 
behavior of the A53T transgenic mice and their respective wild type were 
evaluated at ages of 4, 10 and 16 months. 
The open field apparatus consisted of a Plexiglas square arena (45 x 45 
cm, 40 cm high) that was placed in a homogenously lit experimental room. For 
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each test, mice were placed individually into the center square and were 
allowed to explore it for 15 min. Total traveled distance was measured using a 
video-tracking software.  
 
3.4.2 Pole Test 
 
Pole test was first designed for use with mice by Ogawa and colleagues 
(Ogawa et al., 1985). It assesses the agility of animals and may be a measure 
of bradykinesia (Ogawa et al., 1985). This task involves skilled forelimb 
grasping and maneuvering, which would require an intact basal ganglia and 
activation of the rubrospinal pathway. This task, therefore, is very sensitive to 
nigrostriatal dysfunction (Fleming et al., 2004; Ogawa et al., 1985; Hwang et al., 
2005; Ogawa et al., 1987; Matsumura et al., 1997). 
 The test consists by placing the mouse head up-ward on the top of a 
vertical rough-surfaced pole (diameter 1cm; height 55cm) and recording the 
time spent by the mouse to reach the floor. The behavior was scored until the 
mouse reached the floor. For each experimental section, animals received 3 
trials and the average scorers were expressed in seconds.  
 
3.4 Statistical analysis 
 
Data were generated from a minimum of 3 independent experimental 
sessions for in vitro studies, and at least 8 animals for each experimental group 
for in vivo experiments. Calcium measurements were performed at least in 20 
cells for each of the 3 independent experimental sessions. Data were 
expressed as mean±S.E.M. Statistical comparisons between transgenic and 
wild type mice and cells and their respective controls were performed using the 
one-way ANOVA test, followed by Newman Keul’s test. P value <0.05 was 
considered statistically significant. 
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4. RESULTS 
4.1 NCX expression in A53T transgenic mice during aging. 
 
To investigate the expression of the three isoforms of NCX, i.e. NCX1, 
NCX2, NCX3, during aging, mice expressing human A53T variant -synuclein 
were sacrificed at the age of 4, 10 and 16 months old. Brains were removed; 
midbrain and striatum were isolated and processed by Western blotting. The 
results obtained showed that NCX1 expression was increased only in the 
striatum of 10 months old transgenic mice (Fig. 3B) while its expression did not 
change in the midbrain of the same animals in comparison with 10 months old 
wild type mice (Fig. 3A). 
 
Fig. 3 NCX1 expression in midbrain (A) and in striatum (B) of 4, 10 and 16 months old 
A53T transgenic and wilde type mice. The bar graphs report the mean ±SEM of the 
densitometric values of NCX1 band intensity obtained in midbrain and striatum of transgenic 
and wild type mice and normalized to the respective tubulin. WT= wild type; TG= transgenic 
A53T. *p<0.05 vs respective WT controls. 
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Conversely, NCX2 expression did not change during aging in the striatum 
of transgenic mice compared to the respective Wt controls (Fig. 4B), whereas 
its expression was reduced in the midbrain of 4 months old mice  (Fig. 4A) 
compared to the respective wild type mice. 
 
Fig. 4 NCX2 expression in midbrain (A) and in (B) striatum of 4, 10 and 16 months old 
A53T transgenic and wild type mice. The bar graphs report the mean ±SEM of the 
densitometric  values of NCX2 band intensity obtained in midbrain and striatum of transgenic 
and wild type mice and normalized to the respective  tubulin. WT= wild type; TG= transgenic 
A53T. *p<0.05 vs respective WT. 
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On the other hand, NCX3 expression was reduced only in the midbrain of 
10 months old A53T transgenic mice respect to wild type (Fig 5A), whereas no 
change in the striatum was observed in Tg and Wt mice during aging (Fig 5B). 
 
Fig. 5 NCX3 expression in midbrain (A) and (B) striatum of 4, 10 and 16 months old A53T 
transgenic and wild type mice. The bar graphs report the mean ±SEM of the densitometric 
values of NCX3 band intensity obtained in midbrain and striatum of transgenic and wild type 
mice and normalized to the respective tubulin. WT= wild type; TG= transgenic A53T. *p<0.05 vs 
respective WT.  
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amount of α-synuclein protein expression during aging, since it is well known 
that α-synuclein deposition occurs in the Lewy bodies found in damaged 
neurons during PD (Spillantini et al., 1998a,b). The results obtained showed 
that an increase in α-synuclein expression occurs in both midbrain (Fig. 6A) and 
striatum (Fig.6B) of A53T transgenic mice during aging, whereas no α-synuclein 
accumulation was detected in Wt brain at the same times. 
 
 
Fig. 6 α-synuclein expression in midbrain (A) and striatum (B) of 4, 10 and 16 months old 
A53T transgenic and wild type mice. The bar graphs report the mean ±SEM of the 
densitometric values of α-synuclein band intensity obtained in midbrain (A) and in striatum (B) of 
transgenic and wild type mice and normalized to the respective actin. WT= wild type; TG= 
transgenic A53T. *p<0.05 vs respective WT, **p<0.05 vs 4 months TG, ***p<0.05 vs 16 months 
TG. 
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4.3 Tirosyne Hydroxylase expression in A53T transgenic mice during 
aging. 
 
Further experiments were performed to verify whether changes in NCX 
protein expression and α-synuclein accumulation might be correlated with loss 
of dopaminergic neurons in A53T transgenic mice in comparison to wild type 
controls. The dopaminergic neuronal loss was assessed by measuring the 
expression of the tyrosine hydroxylase (TH) enzyme, which is one of the main 
markers of dopaminergic neurons. The results obtained showed that in the 
striatum of A53T transgenic mice the expression of TH was reduced during 
aging in comparison with wild type controls (Fig.7B), whereas in the midbrain of 
A53T transgenic mice TH expression was reduced mainly in 4 and 10 months 
old A53T transgenic mice compared to respective wild type mice (Fig.7A). 
 
Fig. 7 Tyrosine Hydroxylase (TH) expression in midibrain (A) and in striatum (B) of 4, 10 
and 16 months old A53T transgenic and wild type mice. The bar graphs report the mean 
±SEM of the densitometric  values of TH band intensity obtained in midbrain (A) and in striatum 
0
0,5
1
1,5
2
2,5
4 Months 10 Months 16 MonthsP
ro
te
in
e
x
p
re
s
s
io
n
T
yr
o
si
n
e
H
yd
ro
x
yl
a
s
e
/A
c
ti
n
 
WT
TG
* *
β-Actin
42 kDA
TH
60 kDA
MIDBRAIN
TH
60 kDA
β-Actin
42 kDA
0
0,5
1
1,5
2
4 Months 10 Months 16 Months
* * *
P
ro
te
in
e
x
p
re
s
s
io
n
T
yr
o
si
n
e
H
yd
ro
x
yl
a
s
e
/A
c
ti
n
 
STRIATUM
(A)
(B)
WT
TG
 41 
(B) of transgenic and wild type mice and normalized to the respective actin. WT= wild type; TG= 
transgenic A53T. *p<0.05 vs respective WT. 
 
4.4 Locomotor activity in A53T transgenic mice during aging.  
  
In order to correlate the alterations in the expression of NCX isoforms, α-
synuclein deposition and neuronal cell loss with motor impairment observed in 
mice expressing human A53T variant of α-synuclein during aging, the locomotor 
activity was assessed in these mice by means of Open Field and the Pole tests.  
The results obtained by means of Open Field test showed that in 16 months old 
transgenic mice a decrease in the spontaneous motor activity occurred. In fact, 
at this time, the ability of mice to explore the arena was lower compared with 
that observed in wild type mice at the same age (Fig. 8). 
 
 
Fig. 8 Spontaneous motor activity in 4, 10, 16 months old Wild type (WT) and A53T 
transgenic mice (TG) monitored in the Open Field test. Values were reported as mean 
±SEM. *p<0.05 Vs WT. 
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Pole test was used to evaluate the imbalance and the bradykinesia in this 
mouse model. Accordingly, mice were placed head upward on the top of a pole 
and the time spent to climb down to the pole until to the floor was recorded. The 
results obtained showed that an impairment in motor activity occurred in A53T 
transgenic mice during aging, since they took more time to climb down to the 
pole compared to wild type mice (Fig. 9). 
 
Fig. 9 The difference of the time spent to climb down from the pole in 4,10 and 16 months 
old wild type (WT) and A53T transgenic mice (TG). Values showed as mean ±SEM.*p<0.05 
vs WT. 
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4.5 NCX and TH expression in midbrain neurons obtained from A53T 
transgenic mice. 
 
Parallel experiments were performed in vitro in primary midbrain neurons 
obtained from A53T transgenic mice embryos and in the respective wild type 
neurons in which Western blot experiments were performed to evaluate the 
modulation of NCX isoforms expression. The results obtained showed that 
among the three isoforms of NCX, NCX3 is the only one whose expression was 
reduced in midbrain neurons (Fig.10). 
 
Fig.10 NCX protein expression in primary midbrain neurons obtained from A53T 
transgenic mice embryos. The bar graphs report the mean ±SEM of the densitometric values 
of NCX band intensity obtained from primary midbrain neurons of transgenic and wild type mice 
embryos and normalized to the respective tubulin. WT= wild type; TG= transgenic A53T. 
*p<0.05 vs respective WT. 
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To verify whether changes of NCX expression in primary midbrain neurons 
were correlated with dopaminergic neuronal loss, Western blotting experiments 
were conducted in these neurons to evaluate the amount of TH protein 
expression. The results showed that expression levels of TH were significantly 
reduced in primary midbrain neurons obtained from A53T transgenic mice 
compared to wild type neurons (Fig.11). 
 
Fig. 11 Tyrosine Hydroxylase (TH) expression in primary midbrain neurons obtained from 
A53T transgenic mice embryos. The bar graphs report the mean ±SEM of the densitometric 
values of TH band intensity obtained from midbrain neurons of transgenic and wild type mice 
and normalized to the respective actin. WT= wild type; TG= transgenic A53T. *p<0.05 vs 
respective WT. 
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4.6 Cytosolic and Mitochondrial calcium concentrations and 
mitochondrial membrane potential in midbrain neurons obtained from 
A53T transgenic mice 
 
Since it has been recently reported that NCX3 is the only NCX isoform 
found on the outer mitochondrial membrane where it plays an important role in 
regulating mitochondrial and cytosolic calcium homeostasis (Scorziello et al., 
2013), further experiments have been performed to understand the role played 
by the impairment of NCX3 protein experession in the progression of neuronal 
damage. To this aim mitochondrial function was investigated in primary 
midbrain neurons obtained from A53T transgenic embryos. In particular, 
mitochondrial membrane potential and mitochondrial calcium concentrations 
were measured by means of confocal microscopy. Parallel experiments were 
performed to measure cytosolic calcium concentration. The results obtained 
showed that both mitochondrial (Fig.12A) and cytosolic (Fig.12B) calcium 
concentrations were increased in transgenic midbrain neurons compared to wild 
type neurons. 
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Fig. 12 Mitochondrial (A) and cytosolic (B) calcium concentrations in midbrain neurons 
obtained from A53T transgenic (TG) and wild type embryos (WT). Values were expressed 
as mean of the percentage ±SEM. *p<0.05 Vs WT 
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Interestingly, a significant mitochondrial hyperpolarisation was observed in 
midbrain neurons obtained from A53T transgenic mice compared to wild type 
neurons (Fig.13).  
 
 
 
 
 
 
 
 
 
 
 
Fig. 13 Mitochondrial membrane potential in midbrain neurons obtained from A53T 
transgenic (TG) and wild type embryos (WT). Values were expressed as mean of the 
percentage ±SEM. *p<0.05 Vs WT. 
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5. DISCUSSION 
 
The results of the present study demonstrate that the three isoforms of the 
Na+/Ca2+ exchanger are differently modulated in midbrain and in striatum in 
A53T transgenic mice during aging, a genetic model of PD. In particular, in 
A53T 4 months old transgenic mice NCX2 is the only NCX isoform whose 
expression was reduced in midbrain, whereas the expression of NCX1 and 
NCX3 did not change in comparison to WT mice. Interestingly, at this time the 
expression of TH protein was reduced, thus suggesting that the decrease in 
NCX2 expression might be considered as an early maker of dopaminergic 
neuronal degeneration. This hypothesis is in line with results previously 
reported by Shin and Colaborators (Jeon et al 2003), who demonstrated that 
NCX2 works as a temporal regulator of calcium homeostasis and, as such is 
essential for synaptic plasticity. Therefore, we argued that in our experimental 
condition, the reduced expression of NCX2 by slowing intracellular calcium 
clearance, might stimulate DA release and in turn promote oxidative stress and 
neuronal loss. 
Conversely, NCX1 protein expression was found increased in striatum in 
10 months A53T transgenic old mice, whereas no changes in NCX1 expression 
were found in midbrain at this time. Moreover, an impairment in TH protein 
expression was also detected in striatum of A53T transgenic mice compared 
with WT 10 months old mice, thus suggesting that the increase in NCX1 might 
play a role in dopaminergic neuronal death. This hypothesis is in line with the 
results reported by Ago and colleagues (2011) in a mouse model of PD. In fact, 
they demonstrated that the inhibition of NCX1 by SEA0400 in mice treated with 
MPTP ameliorates motor activity and reduces dopaminergic neuronal loss 
probably by blocking ERK phosphorylation and lipid peroxidation, two effects 
downstream of NCX-mediated Ca2+ influx.  These findings support the idea that 
NCX1 activation might have detrimental role in PD. Moreover, the fact that in 
our study the increase in NCX1 expression was detected in A53T transgenic 
mice bearing the human mutation of -synuclein in that brain area in which an 
abnormal deposition of -synuclein occurs, further highlight the involvement of 
NCX1 in the pathogenesis of PD.  
 49 
Similarly, in A53T transgenic mice an increase in -synuclein deposition 
was observed in midbrain during aging. However, in this brain area a reduction 
in NCX3 protein expression accompanied with an impairment in the expression 
of TH was detected. Conversely, in Wt mice no change in -synuclein 
deposition was detected and consequently NCX3 protein expression and TH 
were normally expressed.  These findings also suggest that a reduction in 
NCX3 expression might be correlated with neuronal damage in PD.  It is well 
known that NCX1 and NCX3 are plasmamembrane proteins, which play a 
crucial role in the regulation of sodium and calcium homeostasis in physiological 
and pathological conditions (Annunziato et al., 2004; Pignataro et al., 2004; 
Pannaccione et al., 2012). Therefore, it is possible to speculate that an 
alteration in NCX1 and NCX3 protein expression in two brain regions, which 
represent the core of dopaminergic circuits might be associated with a 
perturbation in intracellular calcium concentration which in turn leads to the 
selective neuronal degeneration observed in PD. This hypothesis is supported 
by the finding that in the mouse model used in the present study, an impairment 
in locomotor activity and balance was observed during aging in comparison to 
wild type mice.  
The hypothesis that the selective degeneration of SNpc neurons might be 
correlated to elevated intracellular calcium, thus suggesting an alteration of 
calcium homeostasis in the pathogenesis of PD, has been recently revitalized 
(Schmitz and Sulzer, 2007; Chan et al., 2007). Indeed, it has been reported that 
an increased activity of several classes of Ca2+ channels including L-type 
voltage-dependent– and cyclic nucleotide- sensitive channels seem to play a 
key role in the pathogenesis of PD, leading to an alteration of intracellular Ca2+ 
homeostasis. In this scenario, variation in NCX expression and activity, could 
assume a relevant role since it works, together with the other plasma 
membrane and sarco-endoplasmatic pumps, in setting [Ca2+]i at its resting level 
(i.e.100-200 nM). Accordingly, a deregulation of [Ca2+] in cytosol and in 
intracellular Ca2+ stores has been also considered an important feature of 
neuronal degeneration in the SNpc a brain region in which a greater level of 
NCX1 expression has been detected (Papa et al., 2003). Moreover, the 
observation that cells deficient in complex-I showed an alteration in the cytosolic 
calcium handling, reduced mitochondrial calcium accumulation and consequent 
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ATP synthesis (Visch et al., 2004), suggested a possible relationship between 
mitochondrial dysfunction and perturbation of intracellular calcium homeostasis 
in the pathogenesis of PD.  
It has recently reported that among the three isoforms of NCX, NCX3 is 
present on the outer mitochondrial membrane where it plays a role in 
mitochondrial calcium extrusion (Scorziello et al., 2013). In this regard, the 
results of the present study suggest that the increase in intracellular calcium 
concentration and mitochondrial calcium content observed in transgenic 
midbrain neurons is a consequence of NCX3 impairment. This finding strongly 
supports the hypothesis that in this model a relationship between the 
perturbation of intracellular calcium homeostasis and mitochondrial dysfunction 
leads to neuronal degeneration.  Accordingly, there is increasing evidence that 
NCX3, highly expressed in the brain, plays a pivotal role in the maintenance of 
intracellular Na+ and Ca2+ homeostasis in brain ischemia, thus mediating a 
neuroprotective effect (Annunziato et al., 2004; Boscia et al., 2006; Molinaro et 
al.,, 2008; et al., 2013). Moreover, the deletion of the NCX3 gene in mice has 
detrimental consequences on basal synaptic transmission, LTP regulation, 
spatial learning, and memory performance (Molinaro et al., 2011). Finally, it has 
been reported that the absence of NCX3 in the sarcolemma of the muscle fibers 
was associated with an impairment in neuromuscular transmission (Sokolow et 
al., 2004). 
In conclusion, the results reported in the present study let to hypothesize 
that the changes in NCXs expression occurring in midbrain and in striatum of 
A53T mice correlates with loss of dopaminergic neurons probably due to an 
imbalance of the mechanisms involved in the regulation of intracellular calcium 
homeostasis. These findings reveal new potential targets useful to develop 
alternative strategies to treat Parkinson’s disease.  
 
 
 
 
 
 
 
 51 
 
6. REFERENCES 
 
Abeliovich A, Schmitz Y, Farinas I, et al., (2000) Mice lacking alpha-synuclein 
display functional deﬁ cits in the nigrostriatal dopamine system. Neuron. 25: 
239–52. 
Accili, D. et al., (1996) A targeted mutation of the D3 dopamine receptor gene is 
associated with hyperactivity in mice. Proc. Natl. Acad. Sci. U. S. A. 93:1945 – 
1949. 
Ago Y, Kawasaki T, Nashida T, Ota Y, Cong Y, Kitamoto M, Takahashi 
T, Takuma K, Matsuda T. (2011) SEA0400, a specific Na+/Ca2+ exchange 
inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of 
Parkinson’s disease. Neuropharmacology. 61(8):1441-51. 
Akundi RS, Huang Z, Eason J, Pandya JD, Zhi L, Cass WA, Sullivan PG, 
Büeler H. (2011) Increased mitochondrial calcium sensitivity and abnormal 
expression of innate immunity genes precede dopaminergic defects in Pink1-
deficient mice. PLoS One. 6(1):e16038. 
Annunziato L, Pannaccione A, Cataldi M, Secondo A, Castaldo P, Di Renzo G, 
and Taglialatela M. (2002) Modulation of ion channels by reactive oxygen and 
nitrogen species: a pathophysiological role in brain aging? Neurobiol Aging 
23:819–834. 
Annunziato L, Pignataro G, and Di Renzo GF. (2004) Pharmacology of brain 
Na+/Ca2+ exchanger: from molecular biology to therapeutic perspectives. 
Pharmacol Rev. 56:633–654. 
Annunziato L, Cataldi M, Pignataro G, Secondo A, and Molinaro P. (2007) 
Glutamate- independent calcium toxicity: introduction. Stroke. 38 (Suppl 2):661–
664. 
Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM-Y, Trojanowski JQ, 
Iwatsubo T.  (1998) Aggregation of α-synuclein in Lewy bodies of sporadic 
Parkinson’s disease and dementia with Lewy Bodies. American Journal of 
Pathology.152(4):879-884. 
Baik, J-H. et al., (1995) parkinsonian-like locomotor impairment in mice lacking 
dopamine D2 receptors. Nature. 377:424 – 428. 
Bano D, Young KW, Guerin CJ, Lefeuvre R, Rothwell NJ, Naldini L, Rizzuto R, 
Carafoli E, Nicotera P. (2005) Cleavage of the plasma membrane Na+ /Ca2+ 
exchanger in excitotoxicity. Cell. 120, 275–285. 
 52 
Banerjee R, Starkov AA, Beal MF, Thomas B. (2009) Mitochondrial dysfunction 
in the limelight of Parkinson's disease pathogenesis. Biochim Biophys 
Acta.  1792(7):651-63. 
Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L et al., (2008) Red 
blood cells are the major source of alpha-synuclein in blood. Neuro-degener 
Dis. 5: 55–59. 
Berberián G, Forcato D, Beaugé L. (2009) Key role of PTDIns-4,5P2 micro 
domain in ionic regulation of the mammalian heart Na/Ca exchanger. Cell 
Calcium. 45, 546–553. 
Bers D, Despa S. (2009) Na+ /K+ -ATPase, an integral player in the adrenergic 
ﬁght-or- ﬂight response. Trends Cardiovasc Med. 19:111–118. 
Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, 
Greenamyre JT. (2000) Chronic systemic pesticide exposure reproduces 
features of Parkinson's disease. Nat. Neurosci. 3: 1301–1306. 
Bezard E, Dovero S, Prunier C, et al., (2001) Relationship between the 
appearance of symptoms and the level of nigrostriatal degeneration in a 
progressive MPTP-lesioned macaque model of Parkinson’s disease. J. 
Neurosci. 21(17):6853–6861. 
Bezard E, Przedborski S. (2011) A tale on animal models of Parkinson's 
disease. Mov. Disord. 26(6):993-1002. 
Bezard E, Yue Z, Kirik D, Spillantini MG. (2013) Animal models of Parkinson's 
disease: limits and relevance to neuroprotection studies. Mov. Disord. 28(1):61-
70. 
Blaustein MP, Lederer WJ. (1999) Sodium/calcium exchange: its physiological 
implications. Physiol. Rev. 79: 763–854. 
Bonsi, P., Cuomo, D., Picconi, B., Sciamanna, G., Tscherter, A., Tolu, M., 
Bernardi, G., Calabresi, P., and Pisani, A. (2007) Striatal metabotropic 
glutamate receptors as a target for pharmacotherapy in Parkinson’s disease. 
Amino Acids. 32: 189–195. 
Boscia F, Gala R, Pignataro G, de Bartolomeis A, Cicale M, Ambesi-
Impiombato A, Di Renzo G, Annunziato L. (2006) Permanent focal brain 
ischemia induces isoform-dependent changes in the pattern of Na+/Ca2+ 
exchanger gene expression in the ischemic core, periinfarct area, and intact 
brain regions. J. Cereb. Blood Flow Metab. 26: 502-517.  
Boyman L, Hagen BM, Giladi M, Hiller R, Lederer WJ, Khananshvili D. (2011) 
Proton sensing Ca2+ binding domains regulate the cardiac Na+ /Ca2+ exchanger. 
J Biol Chem.   286:28811–28820. 
Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. (2003) 
Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol 
Aging. 24:197–211. 
 53 
Brinkley BR, Barham SS, Barranco SC, Fuller GM. (1974) Rotenone inhibition 
of spindle microtubule assembly in mammalian cells. Exp. Cell Res. 85:41– 46. 
Brooks DJ, Ibanez V, Sawle GV, et al., (1990) Differing patterns of striatal 18F-
dopa uptake in Parkinson’s disease, multiple system atrophy, and progressive 
supranuclear palsy. Ann Neurol. 28(4):547–555. 
Burch D and Sheerin F. (2005) Parkinson's disease. Lancet. 365 (9459):622-7. 
Burke D, Gasdaska P, Hartwell L. (1989) Dominant effects of tubulin 
overexpression in Saccharomyces cerevisiae. Mol. Cell Biol. 9:1049 –1059.  
Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Sudhof TC. (2010) 
α-Synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 
329: 1663–67. 
Butterfield PG, Valanis BG, Spencer PS, Lindeman CA, Nutt JG. (1993) 
Environmental antecedents of young-onset Parkinson’s disease. Neurology. 
43:1150 –1158.  
Büttner S, Faes L, Reichelt WN, Broeskamp F, Habernig L, Benke S, Kourtis N, 
Ruli D, Carmona-Gutierrez D, Eisenberg T, D'hooge P, Ghillebert R, Franssens 
V, Harger A, Pieber TR, Freudenberger P, Kroemer G, Sigrist SJ, Winderickx J, 
Callewaert G, Tavernarakis N, Madeo F. (2013) The Ca2+/Mn2+ ion-pump 
PMR1 links elevation of cytosolic Ca(2+) levels to α-synuclein toxicity in 
Parkinson's disease models. Cell Death Differ. 20(3):465-77. 
Calì T, Ottolini D, Brini M. (2011) Mitochondria, calcium, and endoplasmic 
reticulum stress in Parkinson's disease. Biofactors. 37(3):228-40. 
Calì T, Ottolini D, Negro A, Brini M. (2012) α-Synuclein controls mitochondrial 
calcium homeostasis by enhancing endoplasmic reticulum-mitochondria 
interactions. J Biol Chem. 25;287(22):17914-29.  
Calì T, Ottolini D, Negro A, Brini M. (2013) Enhanced parkin levels favor ER-
mitochondria crosstalk and guarantee Ca(2+) transfer tosustain cell bioenergeti
cs. Biochim Biophys Acta.  1832 (4):495-508. 
Canitano A, Papa M, Boscia F, Castaldo P, Sellitti S, Taglialatela M, and 
Annunziato L (2002) Brain distribution of the Na/Ca2 exchanger-encoding 
genes NCX1, NCX2 and NCX3 and their related proteins in the central nervous 
system. Ann N Y Acad Sci. 976:394–404. 
 54 
Cannon JR, Geghman KD, Tapias V, Sew T, Dail MK, Li C, Greenamyre JT. 
(2013) Expression of human E46K-mutated α-synuclein in BAC-transgenic rats 
replicates early-stage Parkinson's disease features and enhances vulnerability 
to mitochondrial impairment. Exp. Neurol. 240:44-56. 
Canzoniero LM, Rossi A, Taglialatela M, Amoroso S, Annunziato L, Di Renzo 
G. (1992) The Na(+)-Ca2+ exchanger activity in cerebrocortical nerve endings 
is reduced in old compared to young and mature rats when it operates as a 
Ca2+ influx or efflux pathway. Biochim. Biophys Acta. 1107(1):175-8. 
Castaldo P, Cataldi M, Magi S, Lariccia V, Arcangeli S, Amoroso S. (2009) Role 
of the mitochondrial sodium/cal- 456 cium exchanger in neuronal physiology 
and in the 457 pathogenesis of neurological diseases. Prog Neurobiol. 458 
(87):58–79. 
Chan P, DeLanney LE, Irwin I, Langston JW, Di Monte D. (1991). Rapid ATP 
loss caused by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in mouse brain. J 
Neurochem. 57:348–351.  
Chan, C. S., Guzman, J. N., Ilijic, E., Mercer, J. N., Rick, C., Tkatch, T., 
Meredith, G. E., and Surmeier, D. J. (2007) ‘Rejuvenation’ protects neurons in 
mouse models of Parkinson’s disease. Nature 447, 1081–1086. 
Chan CS, Gertler TS, Surmeier DJ. (2009) Calcium homeostasis, selective 
vulnerability and Parkinson’s disease. Trends Neurosci. 32: 249–56. 
Chan CS, Gertler TS, Surmeier DJ.  (2010) A molecular basis for the increased 
vulnerability of substantia nigra dopamine neurons in aging and Parkinson's 
disease. Mov. Disord.  25 Suppl 1:S63-70. 
Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC. (2005) 
α-Synuclein cooperates with CSPα in preventing neurodegeneration. Cell. 123: 
383–96. 
Cheng YF, Zhu GQ, Wang M, Cheng H, Zhou A, Wang N, Fang N, Wang 
XC, Xiao XQ, Chen ZW, Li QL. (2009) Involvement of ubiquitin proteasome 
system in protective mechanisms of Puerarin to MPP(+)-elicited apoptosis. 
Neurosci. Res. 63(1):52-8.  
Chinopoulos C & Adam-Vizi V (2010) Mitochondrial Ca2+ sequestration and 
precipitation revisited. FEBS J. 277, 3637–3651. 
Cohen G. (1984) Oxy-radical toxicity in catecholamine neurons. 
Neurotoxicology.  Spring. 5(1):77-82. 
Colvin RA, Davis N, Wu A, Murphy CA, Levengood J. (1994) Studies of the 
mechanism underlying increased Na+/Ca2+ exchange activity in Alzheimer's 
disease brain. Brain Res. 665:192–200. 
Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr. 
(2000) Acceleration of oligomerization, not ﬁbrillization, is a shared property of 
both alpha-synuclein mutations linked to early-onset Parkinson’s disease: 
 55 
implications for pathogenesis and therapy. Proc Natl Acad Sci USA. 97: 571–
576. 
Czyz A, Kiedrowski L. (2003) Inhibition of plasmalemmal Na+/ Ca2+ exchange 
by mitochondrial Na+/Ca2+ exchange inhibitor 7-chloro-5-(2-chlorophenyl)-1,5-
dihydro- 4,1-benzothiazepin-2(3 H)-one (CGP-37157) in cerebellar granule 
cells. Biochem. Pharmacol. 66: 2409–2411. 
Danzer, K. M., Haasen, D., Karow, A. R., Moussaud, S., Habeck, M., Giese, A., 
Kretzschmar, H., Hengerer, B., and Kostka, M. (2007) Different species of 
alpha-synuclein oligomers induce calcium influx and seeding. J. Neurosci. 27: 
9220–9232. 
Dauer W, Przedborski S. (2003). Parkinson's disease: Mechanisms and 
models. Neuron. 39: 889–909.  
Davidson WS, Jonas A, Clayton DF, George JM. (1998) Stabilization of alpha-
synuclein secondary structure upon binding to synthetic membranes. J Biol 
Chem. 273: 9443–9449. 
Day BJ, Patel M, Calavetta L, Chang LY, Stamler JS. (1999) A mechanism of 
paraquat toxicity involving nitric oxide synthase. Proc Natl Acad Sci USA. 
96:12760 –12765.  
Di Monte D, Jewell SA, Ekstrom G, Sandy MS, Smith MT. (1986) 1-Methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridinium 
(MPP+) cause rapid ATP depletion in isolated hepatocytes. Biochem Biophys 
Res Commun. 137:310–315. 
DiPolo R, Beauge L. (1982)The effects of pH on Ca2+ extrusion mechanisms in 
dialyzed squid axons. Biochim. Biophys. Acta.  688: 237–245  
Doering AE, Lederer WJ. (1994) The action of Na+  as a cofactor in the inhibition 
by cytoplasmic protons of the cardiac Na+ -Ca2+ exchanger in the guinea-pig. J. 
Physiol. (Lond.)   480:9–20. 
Doering AE, Eisner DA, Lederer WJ. (1996) Cardiac Na-Ca exchange and pH. 
Ann. N. Y.  Acad. Sci. 779: 182–198. 
Duchen MR. (2004) Mitochondria in health and disease: perspectives on a new 
mitochondrial biology. Mol Aspects Med.  25:365–451. 
 56 
Exner N, Treske B, Paquet D, Holmström K, Schiesling C, Gispert S, Carballo-
Carbajal I, Berg D, Hoepken HH, Gasser T, Krüger R, Winklhofer KF, Vogel F, 
Reichert AS, Auburger G, Kahle PJ, Schmid B, Haass C. (2007) Loss-of-
function of human PINK1 results in mitochondrial pathology and can be rescued 
by parkin. J. Neurosci. 27(45):12413-8. 
Exner N, Lutz AK, Haass C, Winklhofer KF. (2012) Mitochondrial dysfunction in 
Parkinson's disease: molecular mechanisms and pathophysiological 
consequences. EMBO J.  31(14):3038-62 
Fath T, Ke YD, Gunning P, Gotz J, Ittner LM.  (2009) Primary support cultures 
of hippocampal and substantia nigra neurons. Nature Protocols 4(1): 78-85. 
Feany, M.B. and Bender, W.W. (2000) A Drosophila model of Parkinson’s 
disease. Nature. 404:394–398. 
Fleming SM, Salcedo J, Fernagut PO, et al., (2004) Early and progressive 
sensorimotor anomalies in mice overexpressing wild-type human   alpha-
synuclein. J. Neurosci. 24:9434 –9440.  
Fornai F, Schluter OM, Lenzi P, et al., (2005) Parkinson-like syndrome induced 
by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome 
system and alpha-synuclein. Proc. Natl. Acad. Sci. U S A. 102(9):3413–3418. 
Fortin DL, Troyer MD, Nakamura K, Kubo S, Anthony MD, Edwards RH. (2004) 
Lipid rafts mediate the synaptic localization of alpha-synuclein. J. Neurosci.  24: 
6715–6723. 
Furukawa, K., Matsuzaki-Kobayashi, M., Hasegawa, T., Kikuchi, A., Sugeno, 
N., Itoyama, Y., Wang, Y., Yao, P. J., Bushlin, I., and Takeda, A. (2006) Plasma 
membrane ion permeability induced by mutant alpha-synuclein contributes to 
the degeneration of neural cells. J. Neurochem. 97, 1071–1077. 
Gandhi S, Wood-Kaczmar A, Yao Z, Plun-Favreau H, Deas E, Klupsch 
K, Downward J, Latchman DS, Tabrizi SJ, Wood NW, Duchen MR, Abramov 
AY. (2009) PINK1-associated Parkinson's disease is caused by neuronal 
vulnerability to calcium-induced cell death. Mol. Cell. 33(5):627-38.  
Gao HM, Hong JS, Zhang W, Liu B. (2002) Distinct role for microglia in 
rotenone-induced degeneration of dopaminergic neurons. J. Neurosci. 22:782–
790.  
Garcia-Reitbock P, Anichtchik O, Bellucci A, et al., (2010) SNARE protein 
redistribution and synaptic failure in a transgenic mouse model of Parkinson’s 
disease. Brain. 133: 2032–44. 
Giasson BI, Murray IV, Trojanowski JQ, Lee VM. (2001) A hydrophobic stretch 
of 12 amino acid residues in the middle of alpha-synuclein is essential for 
ﬁlament assembly. J. Biol. Chem. 276: 2380–2386. 
Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. (2002) 
Neuronal alpha- synucleinopathy with severe movement disorder in mice 
 57 
expressing A53T human alpha-synuclein. Neuron. 34(4):521–533. 
Gleichmann, M. and Mattson M. P. (2011) Neuronal Calcium homeostasis and 
dysregulation. Antiox and Redox sig.  7: 1261-1273. 
Ghosh SS, Swerdlow RH, Miller SW, Sheeman B, Parker WD Jr, Davis RE. 
(1999) Use of cytoplasmic hybrid cell lines for elucidating the role of 
mitochondrial dysfunction in Alzheimer's disease and Parkinson's disease. Ann 
N Y Acad Sci. 893:176-91. 
Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. (1998) The 
risk of Parkinson’s disease with exposure to pesticides, farming, well water, and 
rural living. Neurology. 50:1346 –1350. 
Grace, A. A. and Bunney, B. S. (1983) Intracellular and extracellular 
electrophysiology of nigral dopaminergic neurons—2. Action potential 
generating mechanisms and morphological correlates. Neuroscience. 10:317–
331. 
Grant H, Lantos PL, Parkinson C. (1980) Cerebral damage in paraquat 
poisoning. Histopathology 4:185–195.  
Greenamyre, J. T. and Hastings, T. G. (2004) Biomedicine. Parkinson’s—
divergent causes, convergent mechanisms. Science.  304:1120–1122. 
Guigoni C, Dovero S, Aubert I, et al., (2005) Levodopa-induced dyskinesia in 
MPTP-treated macaques is not dependent on the extent and pattern of 
nigrostrial lesioning. Eur. J. Neurosci. 22(1):283– 287. 
Guzman, J. N., Sanchez-Padilla, J., Wokosin, D., Kondapalli, J., Ilijic, E.,  
Schumacker, P. T., and Surmeier, D. J. (2010) Oxidant stress evoked by 
pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature.  468:696–
700. 
Hansen C, Angot E, Bergstrom AL, Steiner JA, Pieri L, Paul G et al (2011) 
alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons 
and seeds aggregation in cultured human cells. J Clin Invest. 121: 715–725. 
Hardy J, Lewis P, Revesz T, Lees A, Paisan-Ruiz C. (Dev 2009) The genetics 
of Parkinson’s syndromes: a critical review. Curr Opin Genetics. 19: 254–265. 
Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E. (2001) beta-
Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-
Parkinsonian factor. Neuron. 32: 213–223. 
Hausdorff JM. (2009) Gait dynamics in Parkinson's disease: common and 
distinct behavior among stride length, gait variability, and fractal-like scaling. 
Chaos. 19(2):026113. 
Healy DG, Falchi M, O’Sullivan SS, et al., (2008) Phenotype, genotype, and 
worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a 
case-control study. Lancet Neurol. 7(7):583– 590. 
 58 
Heikkila R, Cohen G. (1971) Inhibition of biogenic amine uptake by hydrogen 
peroxide: a mechanism for toxic effects of 6-hydroxydopamine. 
Science. 172(3989):1257-8. 
Hettiarachchi NT, Parker A, Dallas ML, et al., (2009) α-Synuclein modulation of 
Ca2+  signaling in human neuroblastoma (SH-SY5Y) cells. J Neurochem. 111: 
1192–201. 
Hilge M, Aelen J, Vuister GW. (2006) Ca2+ regulation in the Na+ /Ca2+ 
exchanger involves two markedly different Ca2+ sensors. Mol. Cell.   22:15–25. 
Hilge M,  Aelen J, Foarce A, Perrakis A, Vuister GW. (2009) Ca2+ regulation in 
the Na+/Ca2+   exchanger features a dual electrostatic switch mechanism. Proc. 
Natl. Acad. Sci. U. S. A.  106: 14333–14338. 
Hilgemann DW, Matsuoka S, Nagel GA, Collins A. (1992a) Steady-state and 
dynamic properties of cardiac sodium-calcium exchange. Sodium-dependent 
inactivation. J. Gen. Physiol. 100: 905–932. 
Hilgemann DW, Collins A, Matsuoka S. (1992b) Steady-state and dynamic 
properties of cardiac sodium-calcium exchange. Secondary modulation by 
cytoplasmic calcium and ATP. J. Gen. Physiol.   100: 933–961. 
Hilgemann DW. (2007) On the physiological roles of PIP 2 at cardiac Na+ /Ca2+ 
exchangers and K(ATP) channels: a long journey from membrane biophysics 
into cell biology. J. Physiol.   582: 903–909. 
Hinkle KM, Yue M, Behrouz B, Dachsel JC, Lincoln SJ, Bowles EE, Beevers JE, 
Dugger B, Winner B, Prots I, Kent CB, Nishioka K, Lin WL, Dickson DW, Janus 
CJ, Farrer MJ, Melrose HR (2012). LRRK2 knockout mice have an intact 
dopaminergic system but display alterations in exploratory and motor co-
ordination behaviors. Molecular Neurodegeneration. 7(25): 1-17. 
Hisata J. (2002) Final supplemental environmental impact statement. Lake and 
stream rehabilitation: rotenone use and health risks. Washington State 
Department of Fish and Wildlife. 
Hughes JT. (1988) Brain damage due to paraquat poisoning: a fatal case with 
neuropathological examination of the brain. Neurotoxicology. 9:243–248. 
Huls S, Hogen T, Vassallo N, et al., (2011) AMPA-receptor-mediated excitatory 
synaptic transmission is enhanced by iron-induced alpha-synuclein oligomers. 
J. Neurochem. 117: 868–78. 
Hüser J and Blatter LA. (1999) Fluctuations in mitochondrial membrane 
potential caused by repetitive gating of the permeability transition pore. 
Biochem. J.  343: 311–317. 
Hwang DY, Fleming SM, Ardayfio P, et al., (2005) 3,4-dihydroxyphe- nylalanine 
reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral 
characterization of a novel genetic model of Parkinson’s disease. J. Neurosci. 
25:2132–2137. 
 59 
Iacopino, A. M. and Christakos, S. (1990) Specific reduction of calcium-binding 
protein (28-kilodalton calbindin-D) gene expression in aging and 
neurodegenerative diseases. Proc. Natl. Acad. Sci. USA. 87: 4078–4082. 
Iravani MM, Syed E, Jackson MJ, Johnston LC, Smith LA, Jenner P. (2005) A 
modified MPTP treatment regime produces reproducible partial nigrostriatal 
lesions in common marmosets. Eur. J. Neurosci. 21(4):841–854. 
Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA et al., (1995) 
The precursor protein of non-A beta component of Alzheimer’s disease amyloid 
is a presynaptic protein of the central nervous system. Neuron. 14: 467–475. 
Iwamoto T, Inoue Y, Ito K, Sakaue T, Kita S, Katsuragi T. (2004) The exchanger 
inhibitory peptide region-dependent inhibition of Na+/Ca2+ exchange by SN-6 
[2-[4-(4-nitrobenzyloxy)benzyl]thiazolidine-4-carboxylic acid ethyl ester], a novel 
benzyloxyphenyl derivative. Mol Pharmacol. 66(1):45-55. 
Jakes R, Spillantini MG, Goedert M. (1994) Identiﬁcation of two distinct 
synucleins from human brain. FEBS Lett. 345: 27–32. 
Jan C, Pessiglione M, Tremblay L, Tande D, Hirsch EC, Francois C. (2003) 
Quantitative analysis of dopaminergic loss in relation to functional territories in 
MPTP-treated monkeys. Eur. J. Neurosci. 18(7):2082–2086 
Jankowsky, J.L. et al., (2002) Transgenic mouse models of neurode- generative 
disease: opportunities for therapeutic development. Curr. Neurol. Neurosci. 
Rep. 2:457 – 464. 
Jeon D, Yang YM, Jeong MJ, Philipson KD, Rhim H, Shin HS. (2003) Enhanced 
learning and memory in mice lacking Na+/Ca2+ exchanger 2. Neuron. 38(6):965-
76. 
Jo E, McLaurin J, Yip CM, St George-Hyslop P, Fraser PE. (2000) alpha-
Synuclein membrane interactions and lipid specificity. J. Biol. Chem. 
275(44):34328-34. 
Jonsson G. (1980) Chemical neurotoxins as denervation tools in neurobiology. 
Annu Rev Neurosci. 1980;3:169-87. 
Jonsson G. Chemical lesioning techniques: monoamine neurotoxins. In: 
Handbook of chemical neuroanatomy. Methods in chemical neuroanatomy 
(Bjorklund A, Hokfelt T, eds), Ed 1, Vol 1, pp 463–507. Amsterdam: Elsevier 
Science Publishers B.V., 1983. 
Jonsson G, Kasamatsu T. (1983) Maturation of monoamine neurotransmitters 
and receptors in cat occipital cortex during postnatal critical period. Exp. Brain 
Res. 50(2-3):449-58. 
 60 
Juhaszova M, Shimizu H, Borin ML, Yip RK, Santiago EM, Lindenmayer 
GE, Blaustein MP. (1996) Localization of the Na(+)-Ca2+ exchanger in vascular 
smooth muscle, and in neurons and astrocytes. Ann N Y Acad Sci.779:318-35. 
Karpinar DP, Balija MB, Kugler S, Opazo F, Rezaei-Ghaleh N, Wender N et al., 
(2009) Pre-ﬁbrillar alpha-synuclein variants with impaired beta-structure 
increase neurotoxicity in Parkinson’s disease models. EMBO J. 28: 3256–3268. 
Kayed R, Sokolov Y, Edmonds B, et al., (2004) Permeabilization of lipid bilayers 
is a common conformation-dependent activity of soluble amyloid oligomers in 
protein misfolding diseases. J Biol Chem. 279: 46363–66. 
Khananshvili D. (2012) The SLC8 gene family of sodium-calcium exchangers 
(NCX)–structure, function, and regulation in health and disease. Mol. Asp. Med. 
34(2-3):220-35 
Kim, B. G., Shin, D. H., Jeon, G. S., Seo, J. H., Kim, Y. W., Jeon, B. S., and 
Cho, S. S. (2000) Relative sparing of calretinin containing neurons in the 
substantia nigra of 6-OHDA treated rat Parkinsonian model. Brain Res. 
855:162–165. 
Kim B and Matsuoka S. (2008) Cytoplasmic Na+-dependent modulation of 
mitochondrial Ca2+ via electrogenic mito-chondrial Na+-Ca2+ exchange. J 
Physiol. 586: 1683–1697. 
Kirik D, Rosenblad C, Bjorklund A. (1998) Characterization of behavioral and 
neurodegenerative changes following partial lesions of the nigrostriatal 
dopamine system induced by intrastriatal 6- hydroxydopamine in the rat. Exp 
Neurol. 152(2):259–277. 
Kish SJ, Shannak K, Hornykiewicz O. (1988) Uneven pattern of dopamine loss 
in the striatum of patients with idiopathic Parkinson’s disease. Pathophysiologic 
and clinical implications. N. Engl. J. Med. 318(14):876–880. 
Kitamura Y, Kosaka T, Kakimura JI, Matsuoka Y, Kohno Y, Nomura 
Y, Taniguchi T. (1998) Protective effects of the antiparkinsonian drugs 
talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced 
apoptotic death in human neuroblastoma SH-SY5Y cells. Mol. 
Pharmacol. 54(6):1046-54. 
Kitamura Y, Shimohama S, Akaike A, Taniguchi T. (2000) The parkinsonian 
models: invertebrates to mammals. Jpn. J. Pharmacol. 84(3):237-43. 
Kitamura, Y. et al., (2003) Neuroprotective mechanisms of antiparkin-   sonian 
dopamine D2-receptor subfamily agonists. Neurochem. Res. 28:1035 – 1040  
 61 
Koch A, Lehmann-Horn K, Dächsel JC, Gasser T, Kahle PJ, Lücking CB. (2009) 
Proteasomal inhibition reduces parkin mRNA in PC12 and SH-SY5Y cells. 
Parkinsonism Relat. Disord. 15(3):220-5.  
Kordower JH, Chu Y, Hauser RA, Olanow CW, Freeman TB. (2008b) 
Transplanted dopaminergic neurons develop PD pathologic changes: a second 
case report. Mov. Disord. 23:2303–2306. 
Kostka M, Hogen T, Danzer KM, et al (2008). Single particle characterization of 
iron-induced pore-forming α-synuclein oligomers. J. Biol. Chem. 283: 10992–
1003. 
Kramer ML, Schulz-Schaeffer WJ. (2007) Presynaptic alpha-synuclein 
aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy 
bodies. J. Neurosci. 27:1405–10. 
Kurowska Z, Englund E, Widner H, Lindvall O, Li JY, Brundin P (2011) Signs of 
degeneration in 12–22-year old grafts of mesencephalic dopamine neurons in 
patients with Parkinson’s disease. J Park Dis. 1:83–92. 
Langston JW, Ballard P, Irwin I. (1983). Chronic parkinsonism in humans due to 
a product of meperidine-analog synthesis. Science.  219: 979–980. 
Larsen KE, Schmitz Y, Troyer MD, et al., (2006) α-Synuclein overexpression in 
PC12 and chromaffinn cells impairs catecholamine release by interfering with a 
late step in exocytosis. J Neurosci. 26:11915–22. 
Lashuel, HA, Petre, BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT Jr. 
(2002) Alpha-synuclein, especially the Parkinson’s disease-associated mutants, 
forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322:1089–1102. 
Levitsky DO, Nicoll DA, Philipson KD. (1994) Identiﬁcation of the high afﬁnity 
Ca2+-binding domain of the cardiac Na+-Ca2+ exchanger. J. Biol. Chem.  269: 
22847–22852  
 62 
Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, 
Rehncrona S, Björklund A, Widner H, Revesz T, Lindvall O, Brundin P. (2008) 
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest 
host-to-graft disease propagation. Nat. Med. 14(5):501-3.  
Li L, Nadanaciva S, Berger Z, Shen W, Paumier K, Schwartz J, Mou K, Loos 
P, Milici AJ, Dunlop J, Hirst WD. (2013) Human A53T α-synuclein causes 
reversible deficits in mitochondrial function and dynamics in primary mouse 
cortical neurons. PLoS One. 31:8(12):e85815. 
Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, et al., (1997) 
Environmental risk factors and Parkinson’s disease: a case-control study in 
Taiwan. Neurology. 48:1583–1588. 
Liu G, Zhang C, Yin J, Li X, Cheng F, Li Y, Yang H, Uéda K, Chan P, Yu S.  
(2009) alpha-Synuclein is differentially expressed in mitochondria from different 
rat brain regions and dose-dependently down-regulates complex I activity. 
Neurosci. Lett. 454(3):187-92. 
Liu Z, Hamamichi S, Lee BD, et al., (2011) Inhibitors of LRRK2 kinase attenuate 
neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans 
and Drosophila Parkinson’s disease models. Hum. Mol. Genet. 20(20):3933–
3942. 
Livigni, A., Scorziello, A., Agnese, S., Adornetto, A., Carlucci, A., Garbi, C., 
Castaldo, I., Annunziato, L., Avvedimento, E. V. and Feliciello, A. (2006). 
Mitochondrial AKAP121 links cAMP and src signaling to oxidative metabolism. 
Mol. Biol. Cell .17: 263-271. 
Luk KC, Kehm V, Carroll J, Zhang B, O’Brien P, Trojanowski JQ, Lee VMY 
(2012) Pathological a-synuclein transmission initiates Parkinson-like 
neurodegeneration in nontransgenic mice. Science. 338:949–953. 
Lytton J. (2007) Na+  /Ca2+ exchangers: three mammalian gene families control 
Ca2+ transport. Biochem. J.  406, 365–382. 
Marey-Semper I, Gelman M, Levi-Strauss M. (1995) A selective toxicity toward 
cultured mesencephalic dopaminergic neurons is induced by the synergistic 
effects of energetic metabolism impairment and NMDA receptor activation. J. 
Neurosci. 15:5912–5918. 
Marongiu, R., Spencer, B., Crews, L., Adame, A., Patrick, C., Trejo, M., 
Dallapiccola, B., Valente, E. M., and Masliah, E. (2009) Mutant Pink1 induces 
mitochondrial dysfunction in a neuronal cell model of Parkinson’s disease by 
disturbing calcium flux. J. Neurochem. 108: 1561–1574. 
Maroteaux L, Campanelli JT, Scheller RH. (1988) Synuclein: a neuron-speciﬁc 
protein localized to the nucleus and presynaptic nerve terminal. J Neurosci.  8: 
2804–2815. 
 63 
Marques O, Outeiro TF. (2012) Alpha-synuclein: from secretion to dysfunction 
and death. Cell Death Dis. 3:e350.  
Marshall LE, Himes RH. (1978) Rotenone inhibition of tubulin selfassembly. 
Biochim. Biophys. Acta. 543:590 –594. 
Masliah, E. et al., (2000) Dopaminergic loss and inclusion bodyformation in a-
synuclein mice: implications for neurodegenerative disorders. Science. 
287:1265 – 1269. 
Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA. (2006) LRRK2 in 
Parkinson’s disease: protein domains and functional insights. Trends Neurosci. 
29(5):286–293. 
Matsumura K, Kabuto H, Makino H, Ogawa N. (1997) Pole test is a useful 
method for evaluating the mouse movement disorder caused by striatal 
dopamine depletion. J. Neurosci. Methods.73:45– 48. 
Mattson, M.P. (2007) Calcium and neurodegeneration. Aging cell 6: 337-350.  
Mattson MP, Gleichmann M, Cheng A (2008) Mitochondria in neuroplasticity 
and neurological disorders. Neuron. 60: 748–766. 
McCormack AL, Mak SK, Shenasa M, Langston WJ, Forno LS, Di Monte DA. 
(2008) Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-treated squirrel monkeys. J. Neuropathol. Exp. 
Neurol. 67(8):793–802. 
McCormack AL, Mak SK, Henderson JM, Bumcrot D, Farrer MJ, Di Monte DA. 
(2010) Alpha-synuclein suppression by targeted small interfering RNA in the 
primate substantia nigra. PLoS One. 5(8):e12122. 
McLaughlin S, Wang J, Gambhir A, Murray D. (2002) PIP(2) and proteins: 
interactions, organization, and information  ﬂow. Annu. Rev. Biophys. Biomol. 
Struct.  31:151–175. 
Michaelis ML, Johe K, and Kitos TE (1984) Age-dependent alterations in 
synaptic membrane systems for Ca2+ regulation. Mech. Ageing Dev. 25:215–
225. 
Mishizen-Eberz AJ, Norris EH, Giasson BI, et al., (2005) Cleavage of α-
synuclein by calpain: potential role in degradation of ﬁbrillized and nitrated 
species of alpha-synuclein. Biochemistry. 44: 7818–29. 
Missale, C., Nash, S. R., Robinson, S. W., Jaber, M., and Caron, M. G. (1998) 
Dopamine receptors: from structure to function. Physiol. Rev. 78, 189–225. 
Molinaro P, Cuomo O, Pignataro G, Boscia F, Sirabella R, Pannaccione A, 
Secondo A, Scorziello A, Adornetto A, Gala R, Viggiano D, Sokolow S, 
Herchuelz A, Schurmans S, Di Renzo G, Annunziato L. (2008) Targeted 
disruption of na+/ca2+ exchanger 3 (ncx3) gene leads to a worsening of 
ischemic brain damage. J. Neurosci. 28:1179–1184. 
 64 
Molinaro P, Viggiano D, Nisticò R, Sirabella R, Secondo A, Boscia F, 
Pannaccione A, Scorziello A, Mehdawy B, Sokolow S, Herchuelz A, Di Renzo 
GF, Annunziato L. (2011) Na+ -Ca2+ exchanger (NCX3) knock-out mice display 
an impairment in hippocampal long-term potentiation and spatial learning and 
memory. J Neurosci. 31(20):7312-21. 
Moratalla R, Quinn B, DeLanney LE, Irwin I, Langston JW, Graybiel AM. (1992) 
Differential vulnerability of primate caudate-putamen and striosome- matrix 
dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl- 1,2,3,6- 
tetrahydropyridine. Proc. Natl. Acad. Sci. U S A. 89(9):3859–3863. 
Mosharov EV, Staal RG, Bove J, et al., (2006) α-Synuclein overexpression 
increases cytosolic catecholamine concentration. J Neurosci. 26: 9304–11. 
Mrak, R. E. and Griffin, W. S. (2007) Common inflammatory mechanisms in 
Lewy body disease and Alzheimer disease. J. Neuropathol. Exp. Neurol. 
66:683–686. 
Nakai M, Fujita M, Waragai M, Sugama S, Wei J, Akatsu H et al., (2007) 
Expression of alpha-synuclein, a presynaptic protein implicated in Parkinson’s 
disease, in erythropoietic lineage. Biochem. Biophys. Res. Commun. 358: 104–
110. 
Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, Saad M et al., 
(2011) Imputation of sequence variants for identiﬁcation of genetic risks for 
Parkinson’s disease: a meta-analysis of genome-wide association studies. 
Lancet. 377: 641–649. 
Nemani VM, Lu W, Berge V, et al., (2010) Increased expression of α-synuclein 
reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after 
endocytosis. Neuron. 65: 66–79. 
Nicholls DG (2005) Mitochondria and calcium signaling. Cell Calcium. 38: 311–
317. 
Nicoll DA, Ren X, Ottolia M, Phillips M, Parades AR, Abramson J,.Philipson KD. 
(2007) What we know about the structure of NCX1 and how it relates to its 
function. Ann. NY Acad. Sci. 1099:1–6. 
Obeso JA,  Rodriguez-Oroz  MC, Goetz CG, Marin C, Kordower HJ,  Rodriguez 
M, Hirsch EC, Farrer M, Schapira AHV, Halliday G. (2010) Missing pieces in the 
Parkinson’s disease puzzle. Nature Medicine.16(6): 653-661. 
Ogawa N, Hirose Y, Ohara S, Ono T, Watanabe Y.  (1985) A simple 
quantitative bradykinesia test in MPTP-treated mice. Res. Com- mun. Chem. 
Pathol. Pharmacol. 50:435– 441. 
Ogawa N, Mizukawa K, Hirose Y, Kajita S, Ohara S, Watanabe Y. (1987) 
MPTP-induced parkinsonian model in mice: biochemistry, pharmacology and 
behavior. Eur. Neurol. 26(Suppl. 1):16– 23. 
Paisan-Ruiz C, Jain S, Evans EW, et al., (2004) Cloning of the gene containing 
 65 
mutations that cause PARK8-linked Parkinson’s disease. Neuron. 44(4):595–
600. 
Pannaccione A, Secondo A, Molinaro P, D'Avanzo C, Cantile M, Esposito A, 
Boscia F, Scorziello A, Sirabella R, Sokolow S, Herchuelz A, Di Renzo G, 
Annunziato L. (2012). A new concept: Aβ1-42 generates a hyperfunctional 
proteolytic NCX3 fragment that delays caspase-12 activation and neuronal 
death. J. Neurosci. 32(31):10609-17. 
Papa M, Canitano A, Boscia F, Castaldo P, Sellitti S, Porzig H, Taglialatela M, 
and Annunziato L (2003) Differential expression of the Na-Ca2 exchanger 
transcripts and proteins in rat brain regions. J. Comp. Neurol. 461:31–48. 
Parihar, A., Parihar, M. S., and Ghafourifar, P. (2008) Significance of 
mitochondrial calcium and nitric oxide for apoptosis of human breast cancer 
cells induced by tamoxifen and etoposide. Int. J. Mol. Med. 21: 317–324. 
Parihar, M. S., Parihar, A., Fujita, M., Hashimoto, M., and Ghafourifar, P. (2009) 
Alpha-synuclein overexpression and aggregation exacerbates impairment of 
mitochondrial functions by augmenting oxidative stress in human 
neuroblastoma cells. Int. J. Biochem. Cell Biol. 41: 2015–2024. 
Parker WD Jr, Boyson SJ, Parks JK (1989) Abnormalities of the electron 
transport chain in idiopathic Parkinson's disease. Ann Neurol. 26: 719–723.  
Parker WD Jr, Parks JK, Swerdlow RH. ( 2008 ) Complex I deficiency in 
Parkinson's disease frontal cortex. Brain Res. 1189:215-8. 
Pahwa R, Lyons KE. (2010) Early diagnosis of Parkinson's disease: 
recommendations from diagnostic clinical guidelines. Am J Manag Care. 16 
Suppl Implications:S94-9. 
Peng J, Mao XO, Stevenson FF, Hsu M, Andersen JK. (2004) The herbicide 
paraquat induces dopaminergic nigral apoptosis through sustained activation of 
the JNK pathway. J. Biol. Chem. 279:32626 –32632. 
Perfeito R, Cunha-Oliveira T, Rego AC. (2013) Reprint of: revisiting oxidative 
stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-
resemblance to the effect of amphetamine drugs of abuse. Free Radic. Biol. 
Med. 62:186-201 
Perier C, Bové J, Vila M. (2012) Mitochondria and programmed cell death in 
Parkinson's disease: apoptosis and beyond. Antioxid. Redox Signal. 16(9):883-
95. 
Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB. (2007) 
Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J. 
Neurosci.  27: 3338–3346. 
 66 
Philipson KD, Nicoll DA. (2000) Sodium-calcium exchange: a molecular 
perspective. Annu. Rev. Physiol.  62:111-33. 
Pignataro G, Gala R, Cuomo O, Tortiglione A, Giaccio L, Castaldo P, Sirabella 
R, Matrone C, Canitano A, Amoroso S, Di Renzo G, Annunziato L. (2004) Two 
sodium/calcium exchanger gene products, NCX1 and NCX3, play a major role 
in the development of permanent focal cerebral ischemia. Stroke . 35: 2566–
2570. 
Purisai MG, McCormack AL, Langston WJ, Johnston LC, Di Monte DA. (2005) 
Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-
human primates. Neurobiol. Dis. 20(3):898–906. 
Quednau BD, Nicoll DA, and Philipson KD. (1997) Tissue specificity and 
alternative splicing of the Na1/Ca21 exchanger isoforms NCX1, NCX2, and 
NCX3 in rat. Am. J. Physiol. 272:C1250–C1261. 
Reeves J, Condrescu M. (2008) Ionic regulation of the cardiac sodium-calcium 
exchanger. Channels . Channels (Austin) 2: 322–328. 
Ren Y, Zhao J, Feng J. (2003) Parkin binds to α/βtubulin and increases their 
ubiquitination and degradation. J. Neurosci.  23:3316 –3324.  
Rieker C, Dev KK, Lehnhoff K, et al., (2011) Neuropathology in mice expressing 
mouse alpha-synuclein. PLoS One. 6(9):e24834. 
Rizzuto R, Bernardi P, and Pozzan T. (2000) Mitochondria as all-round players 
of the calcium game. J. Physiol.  529: 37–47,  
Rizzuto R, Pozzan T. (2006) Microdomains of intracellular Ca2+: molecular 
determinants and functional consequences. Physiol. Rev. 86:369–408. 
Sandebring, A, Dehvari, N, Perez-Manso, M, Thomas, KJ, Karpilovski, E, 
Cookson, MR, Cowburn, RF, and Cedazo-Minguez, A. (2009) Parkin deficiency 
disrupts calcium homeostasis by modulating phospholipase C signalling. FEBS 
J. 276, 5041–5052. 
Saner A, Thoenen H. (1971) Model experiments on the molecular mechanism 
of action of 6-hydroxydopamine. Mol. Pharmacol. 7(2):147-54. 
Sawada H, Shimohama S, Tamura Y, Kawamura T, Akaike A, Kimura J. (1996) 
Methylphenylpyridium ion (MPP+) enhances glutamate-induced cytotoxicity 
againstdopaminergic neurons in cultured rat mesencephalon. J. Neurosci. 
Res. 43(1):55-62. 
Scalzo P, Kümmer A, Bretas TL, Cardoso F, Teixeira AL. (2010) Serum levels 
of brain-derived neurotrophic factor correlate with motor impairment in 
Parkinson's disease. J. Neurol. 257(4):540-5. 
Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. (1990) 
Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem.  54: 
823–827.  
 67 
Schmitz, Y. and Sulzer, D. (2007) Parkinson's disease: return of an old prime 
suspect invited review. Neuron. 55:8-10. 
Scholz SW, Houlden H, Schulte C, Sharma M, Li A, Berg D et al., (2009) SNCA 
variants are associated with increased risk for multiple system atrophy. Ann. 
Neurol. 65: 610–614. 
Schuler F, Casida JE. (2001) Functional coupling of PSST and ND1 subunits in 
NADH:ubiquinone oxidoreductase established by photoaffinity labeling. 
Biochim. Biophys. Acta. 1506:79 – 87. 
Schulze DH, Muqhal M, Lederer WJ, Ruknudin AM. (2003) Sodium/calcium 
exchanger (NCX1) macromolecular complex. J. Biol. Chem. 278:28849–28855. 
Schulz-Schaeffer WJ. (2010) The synaptic pathology of alpha-synuclein 
aggregation in dementia with Lewy bodies, Parkinson’s disease and 
Parkinson’s disease dementia. Acta Neuropathologica. 120: 131–143. 
Scorziello A, Santillo M, Adornetto A, Dell'aversano C, Sirabella R, Damiano S, 
Canzoniero LM, Renzo GF, Annunziato L. (2007) NO-induced neuroprotection 
in ischemic preconditioning stimulates mitochondrial Mn-SOD activity and 
expression via Ras/ERK1/2 pathway. J Neurochem.103 (4):1472-80. 
Scorziello A, Savoia C, Sisalli MJ, Adornetto A, Secondo A, Boscia F, Esposito 
A, Polishchuk EV, Polishchuk RS, Molinaro P, Carlucci A, Lignitto L, Di Renzo 
G, Feliciello A, Annunziato L. (2013) NCX3 regulates mitochondrial Ca(2+) 
handling through the AKAP121-anchored signaling complex and prevents 
hypoxia-induced neuronal death. J. Cell Sci. 15:126 (Pt 24):5566-77. 
Scotcher KP, Irwin I, DeLanney LE, Langston JW, Di Monte D (1990) Effects of 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium 
ion on ATP levels of mouse brain synaptosomes. J. Neurochem.  54:1295–
1301. 
Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, Roy SA. (2010) pathologic 
cascade leading to synaptic dysfunction in α-synuclein-induced 
neurodegeneration. J Neurosci. 30: 8083–95. 
Secondo A, Staiano RI, Scorziello A, Sirabella R, Boscia F, Adornetto A, 
Valsecchi V, Molinaro P, Canzoniero LM, Di Renzo G, Annunziato L. (2007) 
BHK cells transfected with NCX3 are more resistant to hypoxia followed by 
reoxygenation than those transfected with NCX1 and NCX2: Possible 
relationship with mitochondrial membrane potential. Cell Calcium. 42: 521–535. 
Shimizu K, Ohtaki K, Matsubara K, Aoyama K, Uezono T, Saito O, et al., (2001) 
Carrier-mediated processes in blood– brain barrier penetration and neural 
uptake of paraquat. Brain Res. 906:135–142. 
 68 
Shimohama S, Sawada H, Kitamura Y, Taniguchi T. (2003) Disease model: 
Parkinson's disease. Trends. Mol. Med. 9(8):360-5. 
Shtifman, A., Zhong, N., Lopez, J. R., Shen, J., and Xu, J. (2011) Altered Ca2+ 
homeostasis in the skeletal muscle of DJ-1 null mice. Neurobiol. Aging. 32:125–
132. 
Sirabella R, Secondo A, Pannaccione A, Scorziello A, Valsecchi V, Adornetto A, 
Bilo L, Di Renzo G, and Annunziato L (2009) Anoxia-induced NF-kappaB-
dependent upregulation of NCX1 contributes to Ca2+ refilling into endoplasmic 
reticulum in cortical neurons. Stroke. 40:922–929.   
Sisalli MJ, Secondo A, Esposito A, Valsecchi V, Savoia C, Di Renzo 
GF, Annunziato L, Scorziello A. (2014) Endoplasmic reticulum refilling and 
mitochondrial calcium extrusion promoted in neurons by NCX1 and NCX3 in 
ischemic preconditioning are determinant for neuroprotection. Cell Death Differ. 
 doi: 10.1038/cdd.2014.32.  
Smith JG. (1988) Paraquat poisoning by skin absorption: a review. Hum 
Toxicol. 7:15–19. 
Sokolow S, Manto M, Gailly P, Molgó J, Vandebrouck C, Vanderwinden JM, 
Herchuelz A, Schurmans S. (2004) Impaired neuromuscular transmission and 
skeletal muscle fiber necrosis in mice lacking Na/Ca exchanger 3. J. Clin. 
Invest. 113(2):265-73. 
Sokolow S, Luu SH, Headley AJ, Hanson AY, Kim T, Miller CA, Vinters HV, 
Gylys KH (2011) High levels of synaptosomal Na(+)-Ca(2+) exchangers (NCX1, 
NCX2, NCX3) co-localized with amyloid-beta in human cerebral cortex affected 
by Alzheimer's disease. Cell Calcium 49:208–216. 
Speciale SG. (2002) MPTP: insights into parkinsonian neurodegeneration. 
Neurotoxicol. Teratol. 24(5):607-20. 
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, et al., (1997) 
Alpha-synuclein in Lewy bodies. Nature. 388:839–840. 
Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. (1998a). 
alpha-Synuclein in ﬁlamentous inclusions of Lewy bodies from Parkinson’s 
disease and dementia with lewy bodies. Proc Natl. Acad. Sci. USA. 95: 6469–
6473. 
MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M (1998b). 
Filamentous alpha-synuclein inclusions link multiple system atrophy with 
Parkinson’s disease and dementia with Lewy bodies. Neurosci. Lett.  251: 205–
208. 
 69 
Starkov AA, Polster BM, Fiskum G. (2002) Regulation of hydrogen peroxide 
production by brain mitochondria by calcium and Bax. J Neurochem. 83(1):220-
8. 
Surmeier, D. J. (2007) Calcium, ageing, and neuronal vulnerability in 
Parkinson’s disease. Lancet Neurol. 6: 933–938. 
Surmeier DJ, Plotkin J, Shen W. (2009) Dopamine and synaptic plasticity in 
dorsal striatal circuits controlling action selection. Curr. Opin. 
Neurobiol.  19(6):621-8. 
Taira, T., Saito, Y., Niki, T., Iguchi-Ariga, S. M., Takahashi, K., and Ariga, H. 
(2004) DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 
5: 213–218. 
Takeuchi H, Yanagida T, Inden M, Takata K, Kitamura Y, Yamakawa 
K, Sawada H, Izumi Y, Yamamoto N, Kihara T, Uemura K, Inoue H, Taniguchi 
T, Akaike A, Takahashi R, Shimohama S. (2009) Nicotinic receptor stimulation 
protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease 
models. J. Neurosci. Res. 87(2):576-85. 
Talpade DJ, Greene JG, Higgins DS Jr, Greenamyre JT. (2000) In vivo labeling 
of mitochondrial complex I (NADH:ubiquinone oxidoreductase) in rat brain using 
[(3)H]dihydrorotenone. J. Neurochem. 75:2611–2621. 
Tsigelny IF, Bar-On P, Sharikov Y, et al., (2007) Dynamics of α-synuclein 
aggregation and inhibition of pore-like oligomer development by β-synuclein. 
FEBS J.  274:1862–77. 
Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M et al., (1993) 
Molecular cloning of cDNA encoding an unrecognized component of amyloid in 
Alzheimer disease. Proc Natl Acad Sci USA.90: 11282–11286. 
Vaarmann, A., Gandhi, S., and Abramov, A. Y. (2010) Dopamine induces Ca2+ 
signaling in astrocytes through reactive oxygen species generated by 
monoamine oxidase. J. Biol. Chem. 285: 25018–25023. 
Verkhratsky A. (2005) Physiology and pathophysiology of the calcium store in 
the endoplasmic reticulum of neurons. Physiol Rev. 85:201–279. 
Vila, M. et al., (2001) Engineered modeling and the secrets of Parkinson’s 
disease. Trends Neurosci. 24 (Suppl.), S49–S55. 
Visch H.J, Rutter GA, Koopman WJH, Koenderink JB, Verkaart S, de Groot T, 
Varadi A, Mitchell K.J, Van den Heuvel LP, Smeitink, JAM, Willems, PHGM. 
(2004) Inhibition of mitochondrial Na+-Ca2+ exchange restores agonist-induced 
ATP production and Ca2+ handling in human complex I deficiency. Journal of 
Biological Chemistry. 279: 40328-40336. 
Volles MJ, Lee SJ, Rochet JC, et al., (2001) Vesicle permeabilization by protoﬁ 
brillar α-synuclein: implications for the pathogenesis and treatment of 
Parkinson’s disease. Biochemistry. 40: 7812–19. 
 70 
Wang, X. J. and Xu, J. X. (2005) Possible involvement of Ca2+ signaling in 
rotenone-induced apoptosis in human neuroblastoma SH-SY5Y cells. Neurosci. 
Lett. 376, 127–132. 
Weber CR, Ginsburg KS, Philipson KD et al., (2001) Allosteric regulation of 
Na/Ca exchange current by cytosolic Ca in intact cardiomyocytes. J. Gen. 
Physiol. 117: 119–131. 
Weinstein B, Solomon F. (1990) Phenotypic consequences of tubulin 
overproduction in Saccharomyces cerevisiae: differences between α-tubulin and 
β-tubulin. Mol. Cell Biol. 10:5295–5304. 
Wenning GK, Geser F. (2003) Multiple system atrophy. Revue Neurologique. 
159(5 Pt 2): 3S31–38. 
Williams AJ and Fry CH. (1979) Calcium–proton exchange in cardiac and liver 
mitochondria. FEBS Lett. 97: 288–292,. 
Wilson, C. J. and Callaway, J. C. (2000) Coupled oscillator model of the 
dopaminergic neuron of the substantia nigra. J. Neurophysiol. 83: 3084–3100. 
Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S et al., (2011) In 
vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci 
USA. 08: 4194–4199. 
Wood-Kaczmar A. (2013) The role of the mitochondrial NCX in the mechanism 
of neurodegeneration in Parkinson's disease. Adv. Exp. Med. Biol. 961:241–
249. 
Xu, M. et al., (1994) Dopamine D1 receptor mutant mice are deficient in striatal 
expression of dynorphin and in dopamine-mediated behavioral responses. Cell . 
79:729 – 742. 
Yamada, T., McGeer, P. L., Baimbridge, K. G., and McGeer, E. G. (1990) 
Relative sparing in Parkinson’s disease of substantia nigra dopamine neurons 
containing calbindin-D28K. Brain Res. 526: 303–307. 
Yavich L, Tanila H, Vepsalainen S, Jakala P. (2004) Role of alpha-synuclein in 
presynaptic dopamine recruitment. J Neurosci. 24: 11165–11170. 
Yue Z. (2009) LRRK2 in Parkinson’s disease: in vivo models and approaches 
for understanding pathogenic roles. FEBS J.; 276(22):6445–6454. 
Yu L, Colvin RA. (1997) Regional differences in expression of transcripts for 
Na+/Ca2+ exchanger isoforms in rat brain.  Brain Res Mol Brain Res. 50(1-
2):285-92. 
Zetterstrom, R.H. et al., (1997) Dopamine neuron agenesis in Nurr1-   deficient 
mice. Science. 276: 248 – 250.  
Zhou, Q-Y. et al., (1995) Targeted disruption of the tyrosine hydroxylase   gene 
reveals that catecholamines are required for mouse fetal   development. 
 71 
Nature. 374:640 – 643.  
Zhou, Q-Y. and Palmiter, R.D. (1995) Dopamine-deficient mice are   severely 
hypoactive, adipsic, and aphagic. Cell. 83:1197 – 1209.  
Zhu XR, Maskri L, Herold C, Bader V, Stichel CC, Gunturkun O, Lubbert H. 
(2007) Non-motor behavioural impairments in parkin-deficient mice. Eur. J. 
Neurosci. 26:1902–1911. 
Zimprich A, Biskup S, Leitner P, et al., (2004) Mutations in LRRK2 cause 
autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 
44(4):601–607. 
Ziviani E1, Tao RN, Whitworth AJ. (2010) Drosophila parkin requires PINK1 for 
mitochondrial translocation and ubiquitinates mitofusin. Proc. Natl. Acad. Sci. U 
S A. 107(11):5018-23. 
Zundorf, G. and Reiser, G. (2011) Calcium dysregularion and homeostasis of 
neuronal calcium in the molecular mechanisms of neurodegenerative diseases 
provide multiple targets for neuroprotection. Antiox. and Redox. sig. 7:1276-
1288. 
 
